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1.1.1. Cell therapy 
The concept of regenerative medicine using the body’s own stem cells and/or growth 
factors to repair tissues might become a reality as initial clinical research endeavors have “teamed-
up” aspiring to develop alternative therapeutic strategies to treat various disorders. Stem cells are 
known as a population of undifferentiated tissue precursor cells capable of self-renewal and 
provision of cells for many tissues. In addition, stem cells could be isolated from a variety of 
sources including embryonic, fetal, and adult tissues.[1] Embryonic stem cells were obtained from 
the inner cell mass of the embryonal blastocyst. It has been already shown that human embryonic 
stem cells can differentiate into derivatives of all three embryonic germ layers. However, due to 
the ethical considerations associated, these cells may be restricted to experimental in vitro studies 
and their therapeutic potential remains arguable.[2] In contrast, adult stem cells have been isolated 
from several tissue sources, including the bone marrow (BM), central nervous system, retina and 
skeletal muscle. The plasticity of adult stem cells can probably generate various lineages of cells, 
different from their original one.[3] Thereafter, these cells can be used for organ regeneration and 
cellular repair in several species, as well as in humans. Thus far, there are no ethical issues for 
adult autologous stem cells. Nonetheless, much experimental work remains to be done before their 
clinical relevance and therapeutic benefits are considered.[4] 
In 1867, the German pathologist Cohnheim was the first to identify mesenchymal stem 
cells (MSCs) in BM as non-hematopoietic stem cells.[5] Dr. Cohnheim’s work raised the 
possibility that BM may differentiate to fibroblasts that synthesize collagen fibers normally and 
during repair of wounds. Evidence is now available that BM contains cells that can differentiate 
into other types of mesenchymal cells, thanks to the pioneer studies by Friedenstein and 
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colleagues.[6] They placed whole BM in tissue culture dishes and removed the non-adherent cells 
after 4 hours, thus discarding most of the hematopoietic cells. They have also reported that the 
adherent cells had a heterogeneous in appearance. Yet, the most tightly adherent cells were spindle 
shaped and formed foci of few cells that began to multiply rapidly after a lag phase (2– 4 days). 
However, after several passages, the adherent cells acquired a more homogeneously fibroblastic 
appearance. These cells were also able to differentiate into colonies that resembled small deposits 
of bone or cartilage. Friedenstein’s research observations were further extended by many other 
scientists coming to a conclusion that the cells isolated by Friedenstein’s method were multipotent 
and could differentiate into osteoblasts, chondrocytes, adipocytes, and myoblasts.[7] Currently, 
they are referred to as either “MSCs”, because of their ability to differentiate into mesenchymal-
type cells, or as “marrow stromal cells” because they arise from the complex array of supporting 
niche found in the bone marrow. 
The ability to culture expand MSCs easily,  differentiate them into different cell types in 
vitro, in addition to their appealing immunologic characteristics, clearly render MSCs a promising 
source of stem cells, for both tissue repair/regeneration and gene therapy.[8] Although local 
transplantation/injection of MSCs represents a potential approach that may be useful in certain 
settings, the potential for minimally invasive delivery of MSCs via systemic infusion is of 
particular interest. However, a significant barrier to the effective implementation of MSC therapy 
is the lack of full understanding of MSC trafficking. The targeted delivery of MSCs has shown 
their engraftment in several tissues, particularly after injury. Their homing is defined as the 
arrest/retention of MSCs within the vasculature of a specific tissue followed by transmigration 
across the endothelial cells. Interestingly, there is much evidence to support the theory of MSC 
homing to tissues, particularly when injured or inflamed, involves migration across endothelial 
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cell layers. The mechanism of MSC homing to tissues and migration across endothelium is not 
fully understood yet. However, it is likely that injured tissues expresses specific ligands/receptors 
to facilitate trafficking, adhesion, and infiltration of MSCs to the site of injury, similar to the 
recruitment of leukocytes to sites of inflammation.[9] It is known that chemokine receptors and 
their ligands are key components implicated in the attraction and migration of leukocytes to sites 
of inflammation. Similarly, it has been shown that MSCs express some of these molecules in 
addition to several adhesion molecules, known to be involved in leukocytic migration across 
endothelium cells, are also expressed on MSCs. Such lack of data describing the exact positioning 
of the MSCs following infusion makes it difficult to determine if the cells remain arrested within 
blood vessels (localization) or have undergone trans-endothelial migration (homing). Interestingly, 
several research endeavors demonstrated that cultured MSCs are able to engraft into healthy, as 
well as injured tissues, then differentiate into several cell types in vivo. Herein, we mention a few 
research studies that highlighted this fact later on. Amongst many research teams, Hofstetter and 
colleagues injected MSCs into the spinal cords of paraplegic rats 1 week after injury.[10] 
Surprisingly, they found that MSCs have guided regeneration through the spinal cord lesion, thus 
promoting recovery. Their work demonstrated that the beneficial effect of MSCs in sites of injury 
may not be necessarily based on their differentiation into the injured cell types, but rather on the 
physical attributes, such as forming guiding strands in the injured spinal cord. 
In another study, MSCs injected into the cavity of heart ventricles where rats with induced 
myocardial infarction depicted a significantly higher cell uptake compared to rats with healthy 
myocardium. Nevertheless, 4 hours later, only less than 1% of the injected cells were retained in 
the infarcted heart. Early infusion also resulted in significantly higher uptake in the heart. 
Therefore, a conclusion was made that MSCs are preferentially attracted to, and retained in, the 
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ischemic tissue.[7] Their conclusion suggests that the injured tissue might express specific 
receptors/ligands to facilitate homing, adhesion, and infiltration of MSCs to the site of injury. 
Nonetheless, such expressed molecules may be down regulated a short time after injury takes 
place. When MSCs were injected via the intravenous (IV) route in rats with myocardial infarction, 
most of the cells were trapped in lungs while a few numbers engraft the heart, liver, and spleen. 
While MSCs can home to the injured heart tissue, they are way less than after direct injection into 
the ventricle.[11]  
Despite the entrapment of MSCs in the lungs, evidence has accumulated that MSCs are 
capable of homing to injured tissues after IV injection. Another example for that is the ability of 
cultured MSCs to migrate into sites of brain injury after being transplanted intravenously in rats 
with cerebral ischemia.[12] Similarly, MSCs delivered by the IV route to treat heart allograft 
rejection in rats migrated to sites of allograft rejection.[13] 
Another example, cultured MSCs have been injected systemically to treat osteogenesis 
imperfecta (OI), a disease in which osteoblasts produce defective type I collagen. Horwitz and co-
workers [14] used BM transplants, after ablative chemotherapy, to treat children with OI. Three 
months later, evidence of new dense bone formation, increase in total bone mineral content, 
increase in growth rate, and reduced frequency of bone fracture in all treated patients. In this study, 
mesenchymal progenitor cells in transplanted BM migrated to the bone tissue and then 
differentiated to osteoblasts whose presence correlated with an improvement in bone structure and 
function.  
Over the past decades, the advances of gene delivery into stem cells have raised hopes 
towards the feasibility of using such stem cell-based gene therapy approaches to provide long-term 
therapeutic impacts.[15] Various studies have deepened our understanding of the behavior of 
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individual stem cells in different tissue microenvironments. In parallel, the implementation of 
more accurate assays for stem cells and enhancement in gene vehicles have increased the gene 
transfer efficiency into MSCs. It is envisaged that a thorough evaluation of human gene therapy 
protocols will lead to a better understanding of the potential of stem cells as a gene therapy strategy 
directed towards both inherent and acquired diseases. Several approaches were introduced to 
deliver transgenes into MSCs. Although viral vectors permit efficient transgene delivery, their 
safety concerns have prompted the search for a non-viral gene delivery alternative.[16] 
Interestingly, the genetically-engineered MSCs may have direct applications on several diseases 
in different types of cells, in various microenvironments, and in different tissues in situ. The ability 
to genetically-engineer MSCs provides a means for long-term expression of therapeutic genes for 
the lifetime of the patient for various disorders. MSCs can be engineered to secrete a variety of 
different proteins, in vitro and in vivo, that could potentially treat a variety of genetic or acquired 
diseases, including bone, cartilage and BM disorders, or even cancer.[15] 
Several research groups have investigated the use of MSCs for gene therapy, including 
transplantation of MSCs transfected with genes coding for vascular endothelial growth factor 
(VEGF) to improve heart function in a rat model of myocardial infarction, MSCs as vehicles to 
deliver interferon-beta protein into tumors in mice, and gene therapy with bone morphogenic 
protein-expressing MSCs to boost bone formation.[17] Various reports have made use gene 
transfection of stem cell in tracking them in vivo by the help of reporter genes. In another study, 
ex vivo-expanded MSCs, transduced with a retroviral construct encoding green fluorescent protein 
(GFP), were infused into adult baboons. Data suggested that MSCs were initially widely distribute 
following systemic infusion. Later on,  they participated in the ongoing cellular turnover and 
replacement in a various tissues.[18] 
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The culture of neural stem cells (NSCs) or neural progenitor cells (NPCs) is an essential 
tool for assessing the molecular mechanisms controlling differentiation in the nervous system. 
Human NPCs can be obtained from brain biopsy or can be differentiated from pluripotent stem 
cells.[19] Regardless of their source, one of the main challenges in this field is to mimic in vitro 
neural development as similar as possible to the in vivo situation. Much has been done in order to 
confirm similarities between cells growing in dishes and cells in vivo context in the brain. Indeed, 
in vitro models have evolved as reliable tools for studying cellular and molecular aspects of neural 
differentiation. 
The NT2 lineage is derived from human testicular embryonic teratocarcinoma and 
differentiates into functional post-mitotic neurons. They resemble stem cells with the potentials of 
self-renewal and neuronal differentiation.[20] The obtained NT2-derived-neurons express many 
neuronal markers, such as cytoskeletal proteins, secretory markers and surface markers. Also, NT2 
cells express nestin and vimentin (neuroepithelial precursor cell markers), while NT2-derived-
neurons express MAP2, NF-L and α-internexin, among other neuronal specific proteins, and 
produce a variety of neurotransmitters, namely GABA and glutamine. Moreover, NT2-derived 
neurons can form functional synapses and have also been used in several transplantation studies 
in experimental animals and in human patients. [21] 
Neuronal differentiation is a complicated process that involves many steps.  First, 
proliferation of the precursor cells, then migration of the neurons to their target regions, neurite 
outgrowth, and finally maturation within synaptic circuits.[22] There are three sources for human 
neurons: embryonic stem cells (ESCs), embryonic germ cells (EGC) and embryonal carcinoma 
cells (ECC). ESCs are derived from inner cell mass of the pre-implanted human embryo. While 
EGC are derived from primordial germ cells obtained from embryonic gonads, ECC could be 
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derived from testicular tumors in adult humans. Human NT2 neurons are obtained from ECC via 
the free-floating aggregate method. Such procedure is based on the proliferation of the precursor 
NT2 cells in vitro in normal medium, differentiation upon addition of retinoic acid (RA) to the 
culture media, expansion of adherent cells, purification using mitotic inhibitors, and finally 
selective trypsinization to obtain pure, post-mitotic neuron.[23] Such “classical” protocol 
comprises 6 weeks of treatment with RA, followed by 2 successive seedings, exposure to mitotic 
inhibitors (7-10 days) and 1-2 selective trypsinization steps to obtain purified fractions of neuronal 
cells. Therefore, the whole process of cell culture takes about 2 months, which is the major 
disadvantage of this “classical” differentiation method. Another attempt to differentiate NT2 cells 
was a cell aggregation procedure that cuts the culturing time in half, [24] resulting in a low 
percentage of neuronal cells in the aggregates, which were hard to purify. 
Cell-based therapy is an alternative approach, for the central nervous system (CNS) 
disorders, in which neurological defects are caused by loss of a defined population of the neurons. 
The major source for cells, used in the transplantation studies, is the fetal embryonic tissue. 
Nevertheless, widespread application of such tissue is hampered by logistic as well as ethical 
concerns. Thereafter, cell lines obtained from human tissues, that could multiply and differentiate 
in vitro into neurons, are a promising source of cells to be used for transplantation. NT2-derived 
neurons (NT2-N) may be considered as a potential source of transplantable neurons.[25] Till now, 
many studies were successful to transplant NT2 neurons into the brains of rodent [25], showing 
that neurons could survive, integrate and differentiate in the intact environment of the host CNS. 
Transplanted neurons could extend neurites, express neuronal markers, survive for up to 15 months 
and show no signs of phenotype reversion. In addition, local environment of host CNS seems to 
play a paramount role in the specification of neurotransmitter phenotypes in NT2 cells. Moreover, 
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and most interestingly, the transplanted undifferentiated NT2 precursor cells did not show any 
tumor formation. [26] Human NT2N cells express markers of cholinergic phenotype, therefore it 
was logical to proceed with the pre-clinical studies to  engraft NT2N cells to restore motor function 
in neurological disorders as amyotrophic lateral sclerosis (ALS) and stroke.[27] The transplants of 
NT2-N into the CNS aim to work in concert to afford the neuroprotection and neuroregeneration. 
Several studies have shown a positive effect of engrafted cells that was based mainly on the 
secretion of trophic factors.[28] The promising findings obtained from animal transplantation 
experiments have generated great expectations for using NT2 neurons in clinical trials. 
Nevertheless, issues such as long-term monitoring of cell survival and progression after 
transplantation still needs to be resolved. 
1.1.2. Gene therapy 
According to the Food and Drug Administration (FDA), gene therapy is defined as “the 
administration of genetic material to modify or manipulate the expression of a gene product or to 
alter the biological properties of living cells for therapeutic use.” Such transfer of genetic materials 
could be done for cells in vitro, in vivo and ex vivo. An essential aspect of gene therapy depends 
on designing a suitable delivery system to carry the correct gene to the affected target cells. Safe 
and effective gene delivery for long-term remains a big challenge for gene therapy. More than 5 
decades after the concept was first introduced, gene therapy is now considered as a promising 
treatment option for various human disorders.[29] Serious adverse effects were encountered in 
early clinical trials. Yet, such hurdles have fueled basic research that led to safer and more efficient 
gene carriers. Gene therapy, in different forms, depicted marked clinical benefits in patients with 
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various clinical conditions, such as blindness, neuromuscular disease, hemophilia, 
immunodeficiencies, and cancer (Fig. 1). 
 
Figure 1. Timeline of salient events of gene therapy, adapted from [30] 
The double-helix structure of deoxyribonucleic acid (DNA) was first described by Watson 
and Crick (1953). Later (in 1961), Howard M Temin's DNA provirus hypothesis was enunciated. 
In 1972, Theodore Friedmann and Richard Roblin proposed that “good DNA” could be used to 
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replace “defective DNA” in people with genetic disorders. This was considered the first suggestion 
to treat genetic disease by gene therapy. In September 1990, DeSilva at the age of 4 had been the 
first subject with severe combined immune deficiency (SCID) to undergo gene therapy in the 
United States. This clinical trial was authorized by the NIH Recombinant DNA Advisory 
Committee (RAC) and the Food and Drug Administration (FDA). The gene coding for functional 
adenosine deaminase (ADA) was transferred by retroviral vectors into T lymphocytes. The 
transfected cells were reinfused back into the girl.[31] Additionally, in 1991, Cynthia at age of 
nine underwent another trial at the national institute of health (NIH) Clinical Center. 
Unfortunately, in September 1999, the 18-year-old boy, Jesse Gelsinger, with an inherited enzyme 
deficiency passed away after 4 days of being treated by injection of genetically altered viruses into 
his liver. This was a direct reason for strict regulations in the research field of this technology. In 
the year 2002, a marked shock to the scientific community happened again when a 3-year-old child 
with SCID who was treated in a clinical trial developed leukemia. Therefore, gene therapy trials 
were frozen again till China’s Food and Drug Administration (CFDA) approved Gendicine® 
(recombinant human p53 adenovirus) in 2003 as the first gene therapy product to treat cancer of 
head and neck. Subsequently, in 2007, British doctors carried out the world’s first clinical trial to 
provide gene therapy for Leber Congenital Amaurosis (LCA), a rare inherited eye disease, where 
RPE65 mutations were targeted by ocular injection of adeno-associated virus (AAV). In 2012, 
Alipogene tiparvovec (marketed under the trade name Glybera®) was the first gene therapy drug 
approved by the European Medicines Agency (EMA) for the treatment of lipoprotein lipase 
deficiency in muscles. Recently, in 2017, is considered distinguished start for gene therapy in 
United States. in August 20, 2017 Kymriah® was approved by the FDA as the first gene therapy 
for acute lymphoblastic leukemia to be marketed in the United States. During the same year, 
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Yescarta®, was approved by FDA for treatment of large B-cell lymphoma. By the end of 2017, 
Luxturana® was approved by FDA as the first gene therapy for the treatment for LCA. 
1.1.3. BMP7 applications 
Bone morphogenetic proteins (BMPs), as extracellular matrix-associated proteins, are 
known to govern a plethora of biological processes. BMPs comprise a variety of members of the 
transforming growth factor-β protein superfamily that actively participate in kidney development, 
digit and limb formation, angiogenesis, tissue fibrosis, and tumor development. Once discovered, 
BMPs have attracted the attention of the scientific community for their fascinating perspectives in 
tissue engineering and regenerative medicine. Therefore, the importance of BMP signals in 
pathophysiology cannot be overstated because of the multitude of dysregulated BMP signaling in 
numerous pathological processes. Clinically, BMP family members have been associated with 
various pathologies, including obesity, diabetes, various vascular diseases as well as cancer and 
its related comorbidities.[32] During years of research, BMP7 has gained the podium for their use 
in the treatment of various disorders. For example, BMP7 alone emerges as a potential therapeutic 
agent that can decrease vascular calcification, for which there is no adequate therapy at present. 
Additionally, the recent discovery of BMP7 in promoting brown adipocyte differentiation and 
thermogenesis offers a new clinical potential. BMP7 triggers commitment of MSCs to a brown 
adipocyte lineage, and subcutaneous injection of these cells into athymic mice results in 
development of adipose tissue containing mostly of the brown subtype. Tail vein injection of 
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adenovirus expressing BMP7 increased brown fat leading to increased energy expenditure, higher 
basal body temperature, suppressing obesity.[33]  
Figure 2: Signaling of BMP in bone cells. [34] 
BMP–Smad signaling boosts almost every step during the differentiation and maturation 
of osteoblasts (Fig. 2). In addition to their roles in bone development, TGF-βs and BMPs are 
known to regulate the maintenance of postnatal bone and cartilage. Moreover, TGF-βs are key in 
coupling bone synthesis by osteoblasts and bone resorption by osteoclasts through osteoclast-
mediated Atp6i-specific extracellular acidification and Cathepsin K-specific extracellular matrix 
proteins. Several BMPs are potent osteogenic agents that were found to possess significant clinical 
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implication to accelerate healing in bone fracture. BMP7 induces the expression of osteoblast-
specific differentiation markers, such as alkaline phosphatase (ALP). In addition, it accelerates 
matrix mineralization. Therefore, recombinant human BMP7 is currently used for spinal fusion, 
fracture healing and dental tissue engineering. More recently, transplantation of the recombinant 
human BMPs (rhBMPs) with autologous stem-cells has also emerged as a promising technique in 
tissue engineering for the regeneration of various body parts. 
On the other side, many studies to date report that BMP7, as well as other BMPs, are over-
expressed in various cancer types. However, changes in gene expression, epigenetic alterations 
and mutations in genes related to BMPs appear to be mostly a characteristic of a certain type of 
cell or tissue, not necessarily any direct nor indirect cause of carcinogenesis. At the time being, no 
reports are available for the adverse carcinogenic events in patients who underwent operations 
using BMP7. However, the lack of reported cases may be due to the relatively recent introduction 
of BMPs to clinical use and extra precautions must be made in determining appropriate dosage 
and length of retention time in the body.[35] 
1.2.  Non-viral gene delivery vectors 
As mentioned before, gene transfection is defined by introducing exogenous nucleic acids 
such as, DNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA) or antisense 
oligonucleotides. Some of these macromolecules depict a large size and a strong negative charge. 
Therefore, their delivery is typically dependent on vectors or carriers. Recently, non-viral delivery 
of genome editing systems could facilitate precise and permanent correction of perturbed genes. 
Zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and 
clustered regularly interspaced short palindromic repeat (CRISPR/Cas) are programmable 
nucleases that can be designed to target -in theory- any gene in a precise manner. All three gene-
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editing systems result in sequence-specific DNA cleavage, at which point the DNA repair 
machinery of the host cell can be harnessed to achieve gene modification. The development of 
advanced gene delivery carriers should increase the potential of gene therapy to treat various 
disorders and to silence, correct or introduce specific genes with trivial side effects. Interestingly, 
recent advances in nanotechnology, material sciences, and nucleic acid chemistry have provided 
promising non-viral delivery systems, some of which are currently under clinical trials as 
summarized in table 1. 
Table 1: Non-viral DNA vectors used in clinical trials. [36] 
Delivery system Gene therapy 
drug 









I Completed NCT00059605 







I Active NCT01502358 
GL67A–DOPE– 
DMPE–PEG 
pGM169/GL67A Cystic fibrosis II Active NCT01621867 
PEI BC-819/PEI Bladder cancer II Active NCT00595088 
BC-819 Ovarian cancer I/II Completed NCT00826150 





I/II Recruiting NCT01435720 
CYL-02 Pancreatic ductal 
adenocarcinoma 
I Completed NCT01274455 
PEG–PEI– 
cholesterol 
EGEN-001 Ovarian, tubal 
and peritoneal 
cancers 
I Recruiting NCT01489371 
II Active NCT01118052 
EGEN-001-301 Colorectal 
peritoneal cancer 
I/II Recruiting NCT01300858 
PEI-mannose– 
dextrose 
DermaVir/LC002 HIV vaccine II Active NCT00711230 
Poloxamer CRL1005– 
benzalkonium chloride 
ASP0113 CMV vaccine III Recruiting NCT01877655 
II Recruiting NCT01903928 




Although being simple in theory, non-viral vectors are complex in practice. In addition to 
the intra/extra cellular barriers, they face quite a big number of other challenges that needs to be 
circumvented in order to increase their gene transfer effectiveness. Moreover, other obstacles 
categorized as production, formulation and storage. 
1.2.1. Cationic lipids 
Lipid-based gene carriers are among the most widely used non-viral vectors. A big list of 
lipid library has been developed for gene transfer. A positively charged hydrophilic head and 
hydrophobic tail with linker structure that connects both has been a common structural feature in 
all of them. The positively charged head groups binds with negatively charged phosphate groups 
in nucleic acids and form a compacted structure, the lipoplexes. Their transfection efficiency 
depends, in a way or another, on their overall geometric shape, number of charged groups per 
molecules, nature of lipid anchor, and linker bondage. Lipoplexes, thanks to their net positive 
charge, can electrostatically interact with negatively charged glycoproteins and proteoglycans of 
cell membrane that may facilitate their cellular uptake. The positively charged lipids, complexed 
with the genetic material, provide protection against intracellular and extracellular digestive 
enzymes, nucleases. Nevertheless,  the main problem with such positive surface charge is that it 
reduces the half-life of lipoplexes circulation in blood limiting its efficiency beyond vascular 
endothelial cells.[37] Therefore, a neutral polymer as polyethylene glycol (PEG) is used as surface 
shielding to circumvent the excessive charge, thus extend the half-life.[38] Though being well-
tolerated by cells, lipoplexes could be cytotoxic beyond 3/1 ratio of lipid:/DNA. In 1987, Felgner 
and colleagues synthesized the first cationic lipid for DNA delivery, DOTMA (the chloride salt of 
1,2-di-O-octadecenyl-3-trimethylammonium propane). Since that date, cationic lipids become one 
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of the most important tools for the delivery of DNA, RNA and many other therapeutic 
molecules.[39] They are easily designed, synthesized and characterized. Presently used lipids 
possess a positively charged hydrophilic head linked to hydrophobic tail (s) by means of a linker 
structure (Fig. 3). 
 




The hydrophilic head consists of cationic (positively charged) groups such as quaternary 
ammonium salts, primary, secondary, tertiary amines, phosphorus, imidazole, pyridinium, 
guanidine, arsenic, etc. As said earlier, this positive charge is key for binding with the anionic 
(negatively charged) phosphate groups of nucleic acids. The linker bond is an important 
determinant of the chemical stability and biodegradability of cationic lipid, and further governs its 
transfection efficiency and cytotoxicity. Based on the structures of linker bonds, they can be 
grouped into many types, such as ether, ester, amide, carbamate, disulfide, urea, acylhydrazone, 
phosphate, and other unusual types (carnitine, vinyl ether, ketal, glutamic acid, aspartic acid, 
malonic acid diamide and dihydroxybenzene). 
The cationic lipid plays many roles in the process of transfection. The head groups 
(positively charged) bind electrostatically to the phosphate group in nucleic acids (negatively 
charged) to form a complex. As well, they facilitate cellular uptake of nucleic acid by direct 
interaction with cell membrane glycoproteins and proteoglycans (negatively charged). In addition, 
the positively charged lipid protects genetic material against intracellular and extracellular 
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nucleases. Moreover, it triggers their endosomal escape thanks to the proton sponge effect. The 
hydrophobic domain determines phase transition temperature, bilayer fluidity, stability of nano 
formulation, DNA protection from nucleases, endosomal escape, DNA release from complex, and 
eventually nuclear trafficking.[40]  
1.2.2. Liposomes 
Liposomes are spherical vesicles having an aqueous core enclosed by one or more 
phospholipid bilayers or lamellae. Lipids comprise fatty acid derivatives with numerous head 
group moieties. Liposomes are composed of one or more simple or functional concentric lipid 
bilayer membranes that enclose hydrophilic spaces (Fig. 4). 
Figure 4: Schematic 











Over the years, different methodologies for large scale liposome preparation have been 
developed and optimized. The techniques for liposome preparation can be divided into (1) bulk 
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methods, in which liposomes are obtained by transfer of phospholipids from an organic phase into 
an aqueous phase, and (2) film methods, where lipid films are initially deposited on a substrate, 
and subsequently hydrated to give liposomes. Recently, various synthetic modifications to 
phospholipids were made to avoid liposome detection and clearance by the immune system, as 
well as to target the afflicted sites.[42] 
Liposomes belong to the lipid-based category of non-viral gene carriers that are widely 
used in gene delivery. Successful examples of liposomes include Lipofectamine® 2000, 
Lipofectin® and LipofectACE®, have been successfully used to deliver genes delivery to cultured 
cells, animals and patients enrolled to clinical trials, phase I and II.[43] Liposomes are mainly 
composed of lipid and/or phospholipid molecules. The success of liposomes to deliver genetic 
material depends on their properties, administration route and the barriers that they face to reach 
their target inside the cells. These hindrances include, but not limited to, stability in the site of 
administration, permeation of particles through epithelial barriers, stability in the bloodstream, low 
target cell specificity, especially when applied through routes that are far from the target, escape 
from the reticuloendothelial system (RES), uptake by the cells and access to the appropriate site 
within the cytosol or nucleus.[44] 
1.2.3. Niosomes 
Niosomes are membranous vesicles that are composed of non-ionic surfactants, 
amphipathic compounds with a net neutral charge. The non-ionic surfactant component of 
niosomes tend to be oriented in a way that hydrophilic ends face the aqueous phase (outward), 
whereas the hydrophobic ends face inward to form a closed bilayer structure that could enclose 
solutes in the aqueous solution. As a consequence, the closed bilayer structure of niosomes has 
hydrophilic inner and outer surfaces, with a sandwiched lipophilic area in between. The non-ionic 
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surfactants are safe and affordable for the use in biomedicine, e.g. as niosome as gene and drug 
carriers for both hydrophilic and hydrophobic drugs. There are several methods for the preparation 
of niosomes. Ether injection, hand shaking, sonication, and microfluidics methods are just to 
mention a few examples.[45] 
Niosomes were first applied by the cosmetic industry in the seventies. They were also 
proposed as potential vehicles for transporting all sorts of drug molecules thanks to their structural 
similarities with liposomes and other colloidal systems. Therefore, niosomes are potential tools for 
targeted drug delivery by promoting sustained release of potential small drugs in specific cells and 
tissues. Additionally, niosomes were found to be stable particles that have ensured enhanced 
stabilities to a good number of encapsulated drugs. As vehicles for various drugs, many routes 
were used to administer drug-loaded niosomes, such as oral (e.g., Methotrexatetopical and 
Flurbiprofen); ocular (e.g., Acetazolamide, Chloramphenicol, Fluconazole) or topical 
administrations (e.g., Erythromycin, Rofecoxib, Minoxidil, and others).[45] Moreover, efficacy 
and safety of these routes have been proven in numerous pre-clinical and clinical studies which 
that have emphasized the biocompatibility, biodegradability and low immunogenicity of niosomal 
components (non-ionic surfactants, cholesterol, fatty acids, in addition to charged molecules). 
Cytotoxicity is a major factor that should not be overlooked when niosomes are used as a 
therapeutic tool. Cationic lipids are well known to have serious cytotoxicity in transfection due to 
their positively charged molecules. Therefore, the incorporation of non-ionic molecules to 
formulate niosomes could reduce such undesirable toxicity. That is why niosomes are way more 
tolerated by transfected cells compared to their anionic or cationic counterparts.[46] All the 
aforementioned properties, in addition to the low cost and ease of preparation, have paved the way 
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for niosomes to stand out versus liposomes and other conventional systems for drug/gene delivery 
(summarized in table 2). 
Recently, several pharmaceutical companies have invested in niosome adaptability by 
utilizing them in various applications (e.g., nutraceuticals, anti-bacterial, antioxidant and anti-
cancer, among others). 
Table 2: Niosomes versus liposomes. [47] 
 Niosomes Liposomes 




Component purity Good Variable 
Preparation and 
storage 
No special conditions required 
Inert atmosphere and low 
temperature 
Stability Very good Low 
Cost Low High 
 
1.3.  Strategies to improve regenerative medicine by cell therapy 
Idealistically, the aim of cell therapy is to replace damaged/aged cells with healthy 
functioning cells in various conditions, including, yet not limited to, congenital defects, tissue 
injuries, autoimmune disorders, and degenerative diseases. Below, we review a number of 
emerging strategies to improve cell-based regenerative medicine. 
1.3.1. Cell microencapsulation 
Cell microencapsulation is simply defined as the immobilization of cells from an outside 
environment within a semi-permeable membrane barrier protecting cells from both mechanical 
stress and components of the host immune system (such as immunoglobulins, complement and 
immune cells).[48] Meanwhile, the membrane allows the inward diffusion of nutrients and oxygen 
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as well as the outward delivery of waste products and therapeutic agents. Additionally, it permits 
cell transplantation without the use of long-term immunosuppressive therapies, which have 
potentially severe side effects. In comparison with other immobilization systems, the high 
surface/volume ratio of the microcapsules increases membrane permeability, ensuring an optimal 
product exchange to ensure adequate cell viability. Cell encapsulation technology displays 
important advantages over other delivery systems because it permits a sustained and controlled 
release of de novo-produced therapeutic molecules. Additional advantages include the 
enhancement of biosafety, because the toxicity caused by a rapid delivery of high concentrations 
of the drug does not occur. Moreover, the genetically modified cells can express any protein 
desired for in vivo therapy without the modification of the host genome. It is possible to create 
small capsules (100-500 µm) and implant them in close contact with the blood stream, improving 
oxygen transfer into the cells, which may be beneficial in certain applications. Eventually, 
microcapsules could be directly injected/transplanted into implantation sites, such as intra 
peritoneally or subcutaneously, reducing the frequency of administration and thus improving 
patient comfort.[49] 
The most widely employed cell microencapsulation method was originally developed by 
Lim and Sun. In recent decades, the initial technique has undergone modifications, leading to 
several methods to produce microcapsules, including extrusion methods, emulsion (thermal 
gelation), microfluidics, and microlithography. Microencapsulation, originally, was based on the 
polyelectrolyte complexation of alginate with a polycation, normally poly-L-lysine (PLL) or poly-
L-ornithine (PLO). These types of microcapsules are commonly referred to as alginate-PLL-
alginate (APA) or alginate PLO-alginate (APO) microcapsules, respectively. Apart from 
microcapsules formed with these polycations, other polymers [such as chitosan, lactose-modified 
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chitosan, oligochitosan, poly(methylene-co-guanidine), sodium silicate, and multilayers] have 
been implemented to coat alginate. The drawback of these materials is that they are associated with 
cytotoxicity and cell necrosis, which has generated much controversy among research groups. 
Unfortunately, it is still unclear which of these strategies is the best for cell encapsulation.[49] 
Using an appropriate encapsulation biomaterial is one of the most important requirements in the 
development of encapsulated cells. These biomaterials play important roles, providing three-
dimensional synthetic extracellular matrix (ECM) that mimics certain beneficial properties of the 
normal ECM and improving protection against immune reaction by isolating encapsulated cells 
from the host immune cells. These materials should have the ability to form a gel in mild and 
physiological conditions (in terms of temperature, pH, and ionic strength). In addition, they must 
be biocompatible and should not interfere with cellular function. Although many types of natural 
and synthetic polymers have been explored, including collagen, hyaluronic acid, or alginate in 
combination with chitosan, agarose, gelatin, and tyramine, the majority of the studies in the field 
of cell encapsulation have employed sodium alginate.[50] 
Alginate polymer is produced by some seaweeds and by some bacterial species, such as 
Pseudomonas aeruginosa. Alginate, extracted from brown algae, has been implemented in a variety 
of biomedical applications. Nowadays, alginates are used primarily as a thickening agent, for 
example in paint and food industry. In addition, they have been used in the production of many 
chemicals such as ammonia, ethanol, and interferons. 
Over the past decades, alginates’ biocompatibility in relation to their composition has been 
controversial.[48] Structurally, alginates are composed of unbranched, linear binary copolymers 
of β-D-mannuronic acid (M) and α-L-guluronic acid (G) residues linked by 1–4 glycosidic bonds. 
It has been reported that alginates with a high M content provoke an inflammatory response by 
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stimulating macrophages to produce cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF). 
In contrast, some research groups found that guluronic acids is associated with more severe 
inflammatory cell overgrowth and adhesions. Meanwhile, others suggested that the presence of 
contaminants had a greater impact on the immune response than the alginate composition (i.e. M/G 
ratio). The extent of contamination, however, appeared to be related to the alginate composition; 
it was observed that the high M alginate presented a higher content in polyphenol, endotoxins and 
proteins compared to the other alginates tested. This controversy might be caused in part by the 
lack of a standard definition for high-G alginate and high-M alginates.  
To evade the negative charge of alginate droplets, they are coated with a polycation to 
stabilize and control the molecular weight cut-off of the microcapsule membrane. PLL is the most 
widely studied polycation for alginate bead coating. In fact, it has been reported that more than 
85% of the articles dealing with cell encapsulation technology published since the original 
manuscript of Lim and Sun, have introduces significant modifications to the alginate–PLL system. 
Since charged PLL is known to be immunogenic, the PLL coated alginate beads undergo a final 
incubation in alginate to form the alginate—PLL–alginate (APA) system. 
Recently, the modification of alginates with various peptides and proteins, to provide 
control over the cell fate, is gaining significant attention. These functional groups ignite the 
intracellular signaling pathways through the focal adhesions that provide tight control over the 
cell-to-matrix interactions. The Arg-Gly-Asp (RGD) peptide sequence derived from fibronectin is 
a natural peptide sequence present in the ECM. Alginate itself does not support cell attachment, 
but it is easily modified by the simple coupling of cell adhesion domains such as the RGD. As a 
result of such a coupling, the interaction between the alginate and the integrin receptors of the 
enclosed cells is improved, enhancing cell survival and functionality. Alginate gels have also been 
Chapter 1 
26  
functionalized with the Asp-Gly- Glu-Ala (DGEA) and Tyr-Ile-Gly-Ser-Arg (YIGSR) sequences 
derived from other ECM proteins to enhance the gels’ adhesive interactions with various cell types. 
Combination of alginate and the ECM has been applied recently in microcapsules, the matter that 
resulted in a synergistic activity of both materials.[51] The microcapsules offer the mechanical 
and material properties of the alginates, which can be controlled with the consideration of some 
issues; at the same time, the ECM increases the bioactivity of the microcapsules to modulate and 
improve the viability and function of the encapsulated cells. Biomimetic microcapsules using 
RGD-alginate have also been employed. These capsules performed the cell adhesion for the 
encapsulated cells and prolonged their long-term functionality and drug release for more than 10 
months, suggesting that these capsules promote the in vivo long-term functionality of the enclosed 
cells and that the mechanical stability of the capsules is improved.[50] 
Another attractive modification is focused on the control of the biodegradation rate of the 
alginates under physiological conditions. An example of such a modification is the partial 
oxidation of the alginate chains so that they become sensitive to hydrolysis. The degree of this 
oxidation as well as the pH and temperature of the media influences the degradation rate of the 
gels. Additionally, MSCs were entrapped in oxidized alginate-fibrin microbeads to achieve a rapid 
degradation profile and the release of the cells in an effort to promote bone engineering. Moreover, 
alginate may also be covalently crosslinked via the addition of bi-functional molecules such as 
poly (ethylene glycol) [PEG] or methacrylate moieties to the alginate chains. The selective 
modification of the alginate resulted in an enhanced covalent stabilization and an increased 
mechanical strength of the alginate beads.[49] 
Collagen is the main component of the ECM of the mammalian connective tissues. Some 
of the advantages it offers include its biocompatibility, abundance in nature, natural ability to 
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anchor cells and degradability mediated by metalloproteases. Its gelation can be induced by 
changes in pH, allowing cells to be encapsulated under mild conditions. However, the challenges 
of using collagen as a material for cell immobilization include the high cost of its purification, the 
natural variability of the isolated collagen, its immunogenicity, and the variation in its enzymatic 
degradation depending on the implant site.[52] A novel drug delivery system based on collagen-
alginate composite structures has been developed to prevent the cell leakage, maintain the cell 
growth, and control the protein secretion. Collagen has been experimentally used to engineer a 
variety of tissues, including skin, bone, heart valves, and ligaments.[53] 
Chitosan is chitin isolated from the exoskeleton of shellfish, and it has a structure similar 
to natural glycosaminoglycans (GAGs). It can be formed into hydrogels by ionic interaction and 
chemical crosslinking with glutaraldehyde. Scaffolds made of this material can be degraded by 
lysozymes, in addition to their ability to support the release of growth factors synthetized by the 
immobilized cells. Thermosensitive chitosan has also been investigated as a material to create an 
aligned cell sheet and to encapsulate MSCs. A crosslinked chitosan hydrogel was used to distribute 
the cells and enable cell growth. The chondrocytes within scaffolds were able to proliferate, exhibit 
an increased metabolic activity, and secrete ECM over 14-days culture period.[54] 
Agarose is another algae-derived polysaccharide; but unlike alginate, the formation of its 
gel microbeads is thermally reversible. Its most appealing qualities include the ease of its 
processing and a wide range of mechanical (e.g. matrix stiffness) and structural (e.g. pore size) 
possibilities, which are influenced by its concentration in the gel and the cooling rate. In addition, 
agarose can be modified to include cell-adhesion moieties. There have been many studies 
involving the enclosure of various cell types in agarose micro particles. In previous research, 
porcine islets were encapsulated in agarose macro beads and transplanted into spontaneously 
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diabetic rats. All the rats that received encapsulated porcine islets did not require exogenous insulin 
therapy for the entire study.[55] 
Poly N-isopropylacrylamide [pNIPAM] is a thermo-responsive and biocompatible polymer 
with a quick phase transition and a low critical solution temperature (approximately 32 ºC). RGD-
conjugated pNIPAM hydrogel micro carriers have been employed as cell culture substrates. In 
addition to cell adhesion applications, cell encapsulation using pNIPAM particles has also been 
reported. In this case, pancreatic cells were encapsulated into pNIPAM-based microcapsules that 
exhibited a reversible sol-to-gel transition at 0 ºC. In another approach, pNIPAM thermo-
responsive hydrogels have been used to immobilize a chondrogenic cell line, revealing that the 
biomaterial did not affect the cell viability or proliferation. The results also demonstrated an 
increase in the synthesis of GAGs during the culture period. This study supported the hypothesis 
that thermally reversible pNIPAM hydrogel may be suitable as an injectable cell carrier and has 
great potential for cartilage repair.[56] 
Gelatin could be obtained by the partial hydrolysis of collagen fibers derived from skin 
dermis, white connective tissue, cartilage, and bone tissue. As a natural macromolecule, its major 
limitation is the variability caused by its derivation from animal tissue, making batch-to-batch 
reproducibility difficult. This problem could be solved by the use of recombinant gelatins with 
defined molecular weights. The formation of gelatin cell micro particles is based on crosslinking 
reactions. Examples of gelatin micro carriers include Spheramine® and Cultispher®. Cultispher® 
gelatin micro carriers (Percell Biolytica AB, Sweden) are commercially available products and 
have been widely evaluated as gelatin cell carriers.[57] These micro carriers supported growth of 
various mammalian cells in vitro and have also been used as biodegradable scaffolds for guided 
tissue regeneration and cell-based therapies in vivo.[56] 
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Other biomaterials employed for cell encapsulation in the form of hydrogels include PEG 
combined with acrylates and methacrylates, hyaluronic acid, and cellulose sulphate.[58] Despite 
the fact that none have been characterized and studied as much as alginate, it is still possible to 
benefit from the advantages that these biomaterials might offer in the development of alternative 
cell based therapeutic strategies. 
Despite the great advances in cell microencapsulation technology providing great promises 
in clinical trials and even practices, there are still numerous limitations that need to be overcome. 
First, there is a significant need to enhance the systemic biocompatibility of encapsulated cells. 
Fibrous tissue tends to proliferate due to activation of host immune response that results in cell 
death (failure of transplant) through complicated mechanisms including excessive production of 
free oxygen species. Moreover, cell necrosis may take place as a result of improper encapsulation 
biomaterials and/or insufficient oxygen and or nutrient supply. Necrotizing cells may compromise 
the healthy neighboring cells and elicit long-term immunogenic responses.[48] Therefore, 
satisfactory survival rate of encapsulated cells in vivo has to be achieved to ensure successful 
transplantation. This brings us back to the first point, using systemically biocompatible 
biomaterials. As well, microcapsules should provide a semi-permeable membrane with balanced 
porosity to protect the encapsulated cells from host immune system, while ensuring adequate 
nutrient supply and disposal of metabolic waste products. Secondly, capsules should impart a 
proper mechanical strength and stability. Therefore, breakage after transplantation is typical for 
poor microcapsules. Subsequently, leakage of encapsulated cells may lead to serious immune 
responses and other unexpected consequences. Thirdly, one type of microcapsule system can never 
be ideal for all cell types. For example, microcapsules made of non-biodegradable materials may 
not be suitable for applications that aim for integration of the encapsulated cells within the host 
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tissue. Lastly, when it comes to clinical practice, regulatory considerations of the encapsulated 
cells should be taken into account. This necessitates comprehensive standardization of 
microcapsule characterization methodologies, such as surface properties, permeability, 
mechanical strength to mention a few. However, many other properties has to be characterized and 
established to ensure systemic biocompatibility and stability of microcapsules.[49] 
1.3.2. Bioprinting technology 
The bioprinting technology has been introduced to the field of tissue engineering as a 
powerful potential tool for building tissue and organ-like structures. This technology allows 
precise assembly of cells and biomolecules in spatially pre-defined spots within the confined three-
dimensional (3D) structures. As well, natural and artificial polymers, their mixtures, and peptides 
are exploited as bioprinting bio inks for regenerative medicine applications.[59] Several 
bioprinting technologies have been developed for various applications in life sciences, such as; 
studying cellular mechanisms, constructing tissues and organs for implantation, including heart 
valves, skin, myocardial tissue, and blood vessels (as summarized in table 3). 
The various bioprinting technologies promise a great potential and to be a paramount tool 
in the field of medicine in the near future. Nevertheless, several challenges remain for building 
complex tissues composed of various cell types in a confined microarchitecture. Moreover, 
microstructures manufactured by bioprinters do not exactly match the native mechanical strength 
of host tissues/organs. Hence, significant improvements are still required to overcome these 
challenges. Interestingly, 4D bioprinting is an emerging field where time is integrated as a fourth 
dimension with the usual 3D bioprinting. In such novel 4D bioprinting, printed structures have the 
ability to change their shapes by time once an external stimulus is introduced. This technology 
enables the re-organization of biomaterials and cells after printing to improve effective cell 
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patterning. Nevertheless, this field is still in its infancy, 4D bioprinting may help to overcome 
many of the current challenges of 3D bioprinting.[60] 
Optimal vascularization is one of the main factors that determines the success of an organ 
transplant since it ensures proper oxygen and nutrient supply. Though several research studies  
Table 3: Applications of bioprinting in tissue engineering. [61] 
Application Bio ink 
Printing 
method 




Micro-extrusion Bone marrow- 
derived hMSCs 
Tougher mechanical 






















Skin matrix that 
resembles structural 
and biological 
features of native skin 



















Micro-extrusion  Neural stem 
cells 
Recovery from CNS 








Alginate-gelatin Micro-extrusion Aortic root sinus 
smooth muscle 





aortic valve retain 
anatomic complexity 









have focused on developing vascularized constructs using bioprinting, further optimizations are 
required in this area of research. Simple portable bioprinters can also be fabricated in the near 
future to address various clinical challenges. As well, further improvements in fabrication 
technologies and bio inks should be aspired to fabricate fully functional tissues/organs for various 
applications in the realm of regenerative medicine.[62] 
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Gene therapy based on non-viral gene carriers is a relatively emerging science, and despite 
the great achievements as yet, scientists still face persistent challenges. Nevertheless, along with 
the promise of gene editing, non-viral delivery methods are likely to become more efficient and 
less toxic. 
  One of the most promising non-viral gene carriers are the niosomes. Though, their use is 
hampered by the limited gene delivery efficacy. Once transfected, stem cells depict promising 
features to become, by themselves, a good gene delivery tool. The main objective of this thesis is 
the use of novel niosome vehicles to transfect stem cells to enhance their potential in regenerative 
medicine. To accomplish the aim of this thesis, we established different objectives: 
1. To develop and characterize a novel niosome formulation based on the cationic lipid 2,3-
di(tetradecyloxy)propan-1- amine (D), combined with polysorbate 80 (DP80 niosomes) for 
hBMP7 gene delivery to mesenchymal stem cells, in vitro.  
2. To investigate the impact of hBMP7 gene overexpression by the transfected MSCs on their 
osteogenic differentiation through the analysis of the alkaline phosphatase activity (ALP), 
Von Kossa staining and ultrastructural analysis by transmission electron microscopy 
(TEM). 
3. To study the effect of the combined use of two nonionic surfactants, poloxamer 188 (P) 
and polysorbate 80 (P80) into niosomes based on 2,3-di(tetradecyloxy)propan-1-amine 
cationic lipid (D) as a gene delivery tool (DPP80 niosomes) for NT2 cells, primary cerebral 
cortex cell culture, and rat in vivo cerebral cortex. 
4. To explore the potential effect of NT2 cells transfected by DPP80 niosomes, to overexpress 















Stem cell-based gene delivery mediated by cationic niosomes for bone 
regeneration 
Noha Attiaa,b,*, Mohamed Mashala,*, Santiago Grijalvoc,d, Ramon Eritjac,d, Jon Záratea,d, Gustavo 
Purasa, d and José Luis Pedraza, d. 
a NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country 
(UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain. 
b Histology and Cell Biology Department, Faculty of Medicine, University of Alexandria, Alexandria, 
Egypt. 
c Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), Spain. 
d Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-
BBN), Spain. 
* Noha Attia and Mohamed Mashal contributed equally to this work. 
 
Nanomedicine: Nanotechnology, Biology and Medicine 







Stem cell-based gene delivery mediated by cationic niosomes for bone 
regeneration 
Abstract 
Bone morphogenetic protein-7 (BMP7) plays a pivotal role in the transformation of mesenchymal 
stem cells (MSCs) into bone. However, its impact is hampered due to its short half-life. Therefore, 
gene therapy may be an interesting approach to deliver BMP7 gene to D1-MSCs. In this 
manuscript we prepared and characterized niosomes based on cationic lipid 2,3-
di(tetradecyloxy)propan-1-amine, combined with polysorbate 80 for gene delivery purposes. 
Niosomes were characterized and combined initially with pCMS-EGFP reporter plasmid, and later 
with pUNO1-hBMP7 plasmid to evaluate osteogenesis differentiation. Additionally, specific 
blockers of most relevant endocytic pathways were used to evaluate the intracellular disposition 
of complexes. MSCs transfected with niosomes showed increased growth rate, enhanced alkaline 
phosphatase activity (ALP) and extracellular matrix deposition which suggested the formation of 
osteoblast-like cells. We concluded that hBMP7-transfected MSCs could be considered not only 
as an effective delivery tool of hBMP7, but also as proliferating and bone forming cells for bone 
regeneration. 
Key words: bone regeneration; stem cells; gene delivery; niosomes 
 
3.1. Introduction 
Bone marrow-derived mesenchymal stem cells (BM-MSCs) have a multi-directional 
differentiation capacity into bone, cartilage, and epithelial cells when cultured in the appropriate 
inductive media.1 Additionally, BM-MSCs are very appealing cells due to their 
immunomodulatory features, allowing for allogeneic administration.2,3 When they are genetically 
modified, their ability to regenerate morbid osseous tissue is notably enhanced, which provides a 
promising ex vivo approach for clinical orthopedic applications.4,5 Several genes have been 
delivered and overexpressed in MSCs to promote both proliferation and differentiation into 
osteoblastic cells.6 
Bone morphogenetic protein-7 (BMP7) is known to be beneficial for attachment, proliferation, as 
well as for differentiation of pre-osteoblasts.6,7 Although the use recombinant human BMP7 
protein, also known as osteogenic protein-1 (OP-1) was approved by FDA to improve the 
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osteogenic differentiation of MSCs, its local stimulatory impact is hampered by diffusion and/or 
degradation leading to a short half-life.8 Therefore, MSC-based hBMP7 gene therapy represents 
an interesting approach since it could boost bone repair by prolonged protein production in a more 
physiologic manner. Furthermore, MSCs supply can be crucial, especially when the number of 
MSCs are reduced in osteoporosis.9 
Non-viral vectors have attracted great attention as safer alternatives of viral-based gene delivery 
vehicles since they can avoid several concerns such as; immunogenic, mutagenic and oncogenic 
effects.10 Additionally, non-viral gene carriers render the ability to deliver large-sized genes and 
are of low production costs. Consequently, the applications of non-viral vectors in clinical trials 
have increased considerably since 2004.11 However, non-viral formulations are still limited, 
mainly by their modest transfection efficiency. Therefore, this topic demands great efforts of the 
scientific community.12 
Niosomes as self-assembled vesicular nano carriers are composed of non-ionic surfactants and 
cationic lipids.13 Being chemically stable, easily handled and well-tolerated formulations,14 
niosomes are considered advantageous over liposomes.15 Our group has recently reported 
encouraging in vitro and in vivo gene delivery applications of a liposomal formulation based on 
the novel cationic lipid 2,3-di(tetradecyloxy)propan-1-amine.16 In light of such findings, our main 
goal was the development of a novel niosome formulation based on the aforementioned cationic 
lipid combined with polysorbate 80 to deliver and transfect hBMP7 plasmid in MSCs. 
Additionally, the impact of such transfection on MSC in vitro osteogenic differentiation was 
evaluated. 
Firstly, niosomes were elaborated by the reverse phase evaporation technique, and characterized 
in terms of size, superficial charge and morphology. As a proof of concept of successful gene 
delivery and expression, pCMS-EGFP reporter plasmid was used to obtain nioplexes in order to 
transfect D1-MSCs, before the transfection efficiency evaluation of nioplexes based on pUNO1-
hBMP7 plasmid. Finally, the impact of hBMP7 gene expression on cell osteogenic differentiation 
was analyzed with alkaline phosphatase activity (ALP), Von Kossa staining and ultrastructural 
analysis by transmission electron microscopy (TEM). 
3.2. Methods 
3.2.1. Production of cationic niosomes 
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 The hydrochloride salt of the cationic lipid 2,3-di (tetradecyloxy)propan-1-amine (DTPA-
Cl) was synthesized by a slight modification of the experimental protocol described previously.17 
Once the cationic lipid was produced, niosomes were elaborated by modified reverse phase 
evaporation technique.18 Briefly, 5mg of cationic lipid were dissolved in 1 ml of dichloromethane, 
and then emulsified in 5 ml of polysorbate 80 (P80) (0.5% w/v). The emulsion was obtained by 
sonication (Branson Sonifier 250®, Branson Ultrasonics Corporation, Danbury, USA) at 45 W for 
30 s. Upon dichloromethane evaporation, a dispersion containing the nanoparticles was formed by 
precipitation of the cationic nanoparticles in the aqueous medium. The resulting niosomes referred 
as DP80 contained both DTPA-Cl and P80 at a molar ration of 1:2. 
Figure 1: Chemical structure of the components of DP80 niosomes (A. Cationic lipid DTPA-Cl, 
B. Polysorbate 80) 
 
3.2.2. Plasmid propagation and elaboration of nioplexes 
pCMS-EGFP reporter plasmid (5541 bp, PlasmidFactory, Bielefeld, Germany), was propagated, 
purified and quantified as previously described.19 pUNO1-hBMP7 plasmid (4497 bp) was 
purchased from InvivoGen (Toulouse, France). Nioplexes (niosome/DNA complexes) were 
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elaborated by mixing an appropriate volume of a stock solution of pCMS-EGFP/pUNO1-hBMP7 
plasmids (0.5 mg/) with different volumes of niosome suspensions (1mg cationic lipid/ml) to 
obtain different cationic lipid/DNA ratios (w/w). The mixture was left for 30 min at room 
temperature to enhance electrostatic interaction. Nioplexes were referred as DP80-EFGP or DP80-
hBMP7 depending on the plasmid used. 
3.2.3. Characterization of niosomes and DP80-EFGP nioplexes 
Particle size and zeta potential (ZP) were determined by dynamic light scattering (DLS) and Laser 
Doppler Velocimetry (LDV) (Zetasizer Nano ZS, Malvern Instruments, UK). Particle size was 
obtained by cumulative analysis. All measurements were carried out in triplicate. The morphology 
of nioplexes was assessed by cryo-TEM analysis.20 Digital images were acquired for samples 
examined by TEM, TECNAI G2 20 TWIN (FEI), operating at an accelerating voltage of 200 KeV 
in a bright-field and low-dose image mode. 
The capacity of niosomes to condense, release and protect DNA from enzymatic digestion was 
performed by agarose gel electrophoresis assay using pCMS-EGFP plasmid. Naked DNA (as 
control) or niosome-complexed DNA samples (200 ng of plasmid/20 μl) were run on agarose gel 
(0.8% w/v), stained with GelRed™. The gel was immersed in a Tris–acetate–EDTA buffer and 
exposed for 30 min to 120 V. Bands were visualized by ChemiDoc™ MP Imaging System (Bio-
Rad, Madrid, Spain). To analyze DNA release from nioplexes at different cationic lipid/DNA mass 
ratios, 20μl of a 2% SDS solution (Sigma-Aldrich, Madrid, Spain) was added to each sample. 
Protection capacity of nioplexes against enzymatic digestion was studied after adding DNase I 
(Sigma-Aldrich, Madrid, Spain) at a final concentration of 1U DNase I/2.5μg DNA. Afterwards, 
mixtures were incubated at 37°C for 30 min. Finally, a 2% SDS solution was added to release 
DNA from nioplexes. 
3.2.4. Culture and characterization of D1-MSCs 
Mouse mesenchymal stem cells (ATCC®CRL-12424™) (D1-MSCs) were cultured in growth 
medium (GM) composed of: Dulbecco’s modified Eagle’s medium (DMEM) (ATCC 30−2002) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin, (both reagents 
from Gibco, Spain). Cell multipotency was determined by differentiation into osteogenic and 
adipogenic lineages as reported in previous work.1 After two weeks, cells were stained with 




Figure 2: Physicochemical characterization of DP80-EGFP nioplexes (A) Effect of cationic 
lipid/DNA ratio (w/w) on both particle size (bars) and ZP (line), n = 3. (B) Cryo-TEM micrographs 
of nioplexes at 16/1 cationic lipid/DNA ratio (w/w). Arrows indicate lamellar pattern. Scale bar 
=200 nm (inset scale bar =50 nm). (C) Binding, SDS-induced release and protection of DNA at 
different cationic lipid/DNA ratios (w/w) of DP80-EGFP- nioplexes visualized by agarose 
electrophoresis. Nioplexes were treated with SDS (lanes 2, 5, 8, 11 and 14) and DNase I + SDS 
(lanes 3, 6, 9, 12 and 15). OC: open circular form, SC: supercoiled form. 
3.2.5. Reporter EGFP plasmid in vitro transfection 
D1-MSCs were seeded at a density of 9 × 104 cells/well in 24-well plates. 24 h later, GM was 
removed, and cells were washed with serum-free Opti-MEM® solution (Gibco®, California, USA). 
Then, cells were exposed to DP80-EFGP nioplexes (1.25 μg DNA) at different cationic lipid/DNA 
ratios (w/w), and incubated in serum-free Opti-MEM® solution for 4 h at 37°C. Subsequently, 
transfection medium was replaced with GM, and cells were allowed to grow for further 48 h until 
fluorescence microscopy imaging (Nikon TSM) and FACSCalibur flow cytometer analysis (BD 
Biosciences, USA). To analyze cell viability, cells were stained with Propidium Iodide (Sigma-
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Aldrich, Madrid, Spain) prior to flow cytometer analysis. Experiments with uncomplexed DNA 
was considered as negative control. Regarding to positive control, both TransIT® 2020 (Mirus, 
Madrid, Spain) (at a ratio of 3µl of reagent/1µg of DNA) and Lipofectamine® 2000 (L2000) 
(Invitrogen, California, USA) were used. A minimum of 10.000 events were acquired and analyzed 
for each sample in triplicate. 
3.2.6. Endocytosis uptake mechanism for nioplexes 
Several uptake inhibitors were used to determine the endocytosis mechanism by nioplexes. 
Genistein and chlorpromazine hydrochloride were used as inhibitors for caveolae-mediated 
endocytosis (CvME) and clathrin-mediated endocytosis (CME), respectively. Methyl-β-
cyclodextrin was used to simultaneously inhibit CvME and CME. Additionally, wortmannin, was 
employed to inhibit macropinocytosis (MPC). 
D1-MSCs were transfected as mentioned in the previous 3.2.5 section, but in this case, nioplexes 
were prepared with FITC-labeled EGFP plasmid (DareBio, Madrid, Spain). Cells were incubated 
for 30 min with genistein 200 μM, methyl- β -cyclodextrin 5 mM and wortmannin 50 nM, and for 
60 min with chlorpromazine hydrochloride 5 μg/ml prior to addition of nioplexes. After 4 h of 
incubation with nioplexes, cells were washed thoroughly with PBS, detached, and analyzed by 
FACSCalibur flow cytometer (BD Biosciences, USA). For each sample, 10.000 events were 
collected and analyzed. Cellular uptake data were expressed as the percentage of FITC-positive 
cells. Naked DNA was used as a negative control. Each sample was analyzed in triplicate. 
3.2.7. Characterization of DP80-hBMP7 nioplexes, in vitro transfection and 
proliferation/cytotoxicity assay 
DP80-hBMP7 nioplexes were characterized at different mass ratios as previously described in the 
section 3.2.3. Subsequently, transfection of D1-MSCs was performed using DP80-hBMP7 
nioplexes using the transfection protocol described in section 3.2.5. After 48 h post-transfection, 
conditioned media was collected, filtered (0.22 µm filters) and preserved at - 80°C until ELISA 
was performed (R&D, UK) to determine the hBMP7 secreted. CCK-8 viability/proliferation assay 
(Sigma Aldrich, Spain) was performed according to manufacturer’s instructions. Color 
development was read at 450 nm (Tecan M200 microplate reader), corrected with reference 
wavelength at 690 nm and normalized against mean value of three blank wells (GM). 
3.2.8. In vitro assessment of osteogenesis 
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Transfection protocol of DP80-hBMP7 nioplexes was applied as mentioned in section 3.2.5. On 
day 2 post-transfection, both cell cultures in transfected and untransfected (control) wells were 
allowed to continue in growth medium/ osteogenic medium (GM/OM) to determine the impact of 
hBMP7 transfection on the osteogenesis potential of D1-MSCs. Therefore, cells were classified in 
four different groups: untransfected culture in GM/OM, transfected culture in GM/OM. After 2 
weeks, the following in vitro assays were performed. 
3.2.8.1. Alkaline Phosphatase (ALP) activity assay 
D1-MSCs from the four groups were washed and 500 µl of GM were added. After 24h of 
incubation, conditioned media were collected, filtered (0.22 µm filters) and ALP activity assay 
was performed according to manufacturer’s instructions. ALP activity of each sample was read at 
405 nm (Tecan M200 microplate reader) and normalized to 100.000 cells. 
3.2.8.2. Von Kossa Staining 
For qualitative assessment of calcium deposits, Von Kossa staining (Abcam, UK) was performed 
as previously reported.21 Micrographs were digitally processed using NIH Fiji© program. 
3.2.8.3. Transmission electron microscopy (TEM) 
D1-MSCs from both untransfected and transfected groups cultured in GM for two weeks were 
detached and pellets were fixed with 2% gluteraldehyde (pH 7.4) for 24h at 4˚C, processed as 
previously reported1 and examined with Philips EM208S TEM. 
3.2.9. Statistical analysis 
Statistical differences between groups at significance levels of ˃95% were calculated by ANOVA 
and Student’s t test. In all cases, P values <0.05 were regarded as significant. Normal distribution 
of samples was assessed by the Kolmogorov- Smirnov test and the homogeneity of the variance 
by the Levene test. Numerical data were presented as mean ± SD. 
3.3. Results 
3.3.1. Physicochemical characterization of niosomes and DP80-EGFP nioplexes 
The size of niosomes was 54.0±0.9 nm with PDI vales of 0.5±0.1 and ZP values of 41.9±7.1mV. 
Figure 2-A depicts size and ZP values of nioplexes at mass ratios from 2/1 to 20/1. The size of 
nioplexes (bars) decreased from 168 nm to 84 nm at cationic lipid/DNA mass ratios of 2/1 and 
16/1, respectively, then increased slightly to 111 nm at 20/1 mass ratio. PDI of all nioplexes were 
less than 0.3 (Table 1, supplementary data). Concerning ZP, readings were clearly increasing from 
-28.9mV at 2/1 mass ratio to +19.2mV at 8/1 mass ratio, while afterwards depicted no notable 
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change. As illustrated in Fig. 2-B, the cryo-TEM-assessed nioplexes (16/1 mass ratio) exhibited a 
discrete imperfectly spherical morphology with no aggregates. Some nioplexes depicted lamellar 
pattern at higher magnification (arrows, Fig 2-B inset). More pictures at lower magnification can 
be observed in Figure 1, on supplementary data. Figure 2-C represents gel retardation assay of 
DP80-EGFP nioplexes prepared at different cationic lipid/ DNA ratios (8/1, 12/1, 16/1 and 20/1). 
Partial condensation of DNA was seen since faint SC bands were observed on 4, 7, 10 and 13 
lanes. However, condensed DNA was released upon the addition of SDS, as can be observed on 
lanes 5, 8, 11 and 14. Moreover, complexed DNA was protected against DNase I enzymatic 
digestion, since clear OC (open circular) and SC (supercoiled) bands were detected on lanes 6, 9, 
12 and 15 compared to the absence of OC/SC bands in lane 3 (free DNA). 
 
Figure 3: D1-MSCs culture (A1), osteogenic (A2) and adipogenic differentiation (A3). (B) Cell 
transfection efficiency and viability at different cationic lipid/DNA ratios (w/w). Percentage of 
EGFP-positive cells (bars), percentage of viable cells (line) and MFI (dashed line), (n = 3). Similar 
symbol (§) indicate insignificant differences among three bars (P˃0.05). *P < 0.05 vs. TransIT® 
2020 and L2000 viability. #P < 0.05 vs. TransIT® 2020 and L200 MFI. (C) Representative overlay 
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micrographs of D1-MSCs 48 h post-transfection via (C1) DP80-EGFP nioplexes (16/1 cationic 
lipid/DNA mass ratio) and (C2) TransIT® 2020. Scale bars: A1, A2, B1 and B2 = 50 μm and A3= 
25 μm. 
3.3.2. In vitro culture, transfection and viability of MSCs by reporter EGFP plasmid 
Cultured D1-MSCs were spindle-shaped adherent, colony forming cells (Fig 3-A1). Upon culture 
in osteogenic or adipogenic media, they demonstrated calcific deposits by Alizarin Red S (Fig 3-
A2) and Oil red O-stained cytoplasmic lipid vacuoles (Fig 3-A3), respectively. In figure 3-B, all 
cationic lipid/DNA ratios (w/w) studied above 4/1 showed considerable percentages of 
transfection. Meanwhile, naked DNA (control) did not elicit any transfection. The mass ratio of 
16/1 represented the best transfection results of 35.9±1.9%, which did neither differ significantly 
from that obtained by TransIT 2020® (40.7±2.5%) nor by L2000 (35.06±0.5%). On the other hand, 
cell viability was higher with TransIT 2020® (p < 0.05) compared to mass ratio of 16/1 (99.1±0.5% 
and 93.6±1.2%, respectively). Regarding mean fluorescence intensity (MFI) obtained by our 
nioplexes at 16/1 as mass ratio, it was markedly higher than that obtained by TransIT 2020® (1792 
a.u. and 1006 a.u, respectively). Similar finding was observed in figure 3-C. L2000 had least 
viability (78.7± 1.3%) and low MFI (891.3± 2.7 a.u.), therefore excluded from further experiments.  
3.3.3. Endocytosis uptake mechanism of nioplexes 
The uptake of nioplexes at 16/1 mass ratio was determined compared to naked DNA (negative 
control). Figure 4-A showed representative dot plots for uptake of both free DNA and DP80 
nioplexes (0.32% and 83%, respectively). Interestingly, we observed that the selective inhibition 
of caveolae-mediated (genistein) or clathrin-mediated (chlorpromazine hydrochloride) uptake 
pathway had significant effects on cellular uptake of nioplexes (p˂ 0.05). However, there was no 
statistically significant difference between both inhibitors.  
When both previously mentioned endocytosis mechanisms were simultaneously inhibited by prior 
treatment with methyl-β-cyclodextrin, an extremely significant difference was observed when 
compared to control group (p˂ 0.0001). Nevertheless, wortmannin, an inhibitor of MPC, did not 
affect the nioplexes internalization (p˃ 0.05).  
3.3.4. Physicochemical characterization of DP80-hBMP7-nioplexes 
Figure 5-A depicts size and ZP values of nioplexes at different mass ratios (from 2/1 to 20/1). The 
size of nioplexes (bars) decreased gradually from 217nm at 2/1 cationic lipid/DNA mass ratio to 
69 nm at 20/1 mass ratio with PDI values less than 0.3 (Table 1, supplementary data). Regarding 
ZP values, readings were clearly increasing from -11.1 mV at 2/1 mass ratio to +26.2mV at 8/1 
Chapter 3 
50  
mass ratio, while afterwards, slowly decreased to +18.3 mV at mass ratio of 20/1. As illustrated in 
figure 5-B, nioplexes, assessed by cryo-TEM, exhibited a discrete spherical/ovoid morphology 
with no notable clumps. Some nioplexes appeared lamellar at higher magnification (arrows, Fig. 
5-B inset). More pictures at lower magnification can be observed in Figure 1, on supplementary 
data. Figure 5-C illustrated that DNA was partially condensed at mass ratio of 4/1, though complete 
capture was discerned at mass ratios of 8/1, 12/1, and 16/1, since no SC bands were observed on 
lanes 7, 10 and 13. Complexed DNA was released after the addition of SDS, as it could be observed 
on lanes 5, 8, 11 and 14. Except for mass ratio of 4/1, captured DNA was protected against DNase 
I enzymatic digestion since clear OC/ SC bands were detected on lanes 9, 12 and 15 in comparison 
to lane 3 (free DNA) due to the unopposed lytic action of the enzyme. 
 
Figure 4: Uptake study of D1-MSCs 4 h post-incubation with FITC-labeled nioplexes. (A) 
Representative dot plots for cellular uptake, (A1) naked DNA (no carrier), (A2) DP80 nioplexes. 
(B) Uptake % (FITC-positive cells) in the presence/absence of endocytosis inhibitors. (Ctrl) 
represents the uptake with no inhibitors. Mean ± SD; n = 3. (*p<0.05, *** p< 0.0001) 
 
3.3.5. Transfection of MSCs by pUNO1 -hBMP7 plasmid 
As can be observed in figure 6 (bars), all studied cationic lipid/DNA ratios (w/w) demonstrated 
significant secretion of hBMP7 protein in comparison to the untransfected cells (controls). The 
mass ratios of 4/1, 8/1 and 12/1 demonstrated the best transfection results (1460 pg/ml), without 
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significant differences observed among them (p ˃0.05), but was still less than secretion obtained 
by TransIT 2020® transfection (2111 pg/ml) (p < 0.05). On the other hand, cell counting assay 
(CCK8) performed immediately after conditioned media was collected (48h post-transfection) 
demonstrated that transfection by nioplexes at ratios of 8/1, 12/1, and 16/1 induced significant cell 
proliferation (164%, 137% and 122%, respectively) compared to control and TransIT 2020® 
groups (100% and 23%, respectively) (Fig 6, line). Nevertheless, cell viability decreased 
significantly to 65% at 20/1 cationic lipid/DNA mass ratio. 
Figure 5: Physicochemical characterization of DP80-hBMP7 nioplexes. (A) Effect of cationic 
lipid/DNA ratio (w/w) on particle size (bars) and zeta potential (line), n = 3. (B) Cryo-TEM 
micrographs of nioplexes at ratio of 8/1 cationic lipid/DNA ratio (w/w). Arrows indicate lamellar 
pattern. Scale bar = 500 nm (inset scale bar =100 nm). (C) Binding, SDS-induced release and 
protection of DNA at different cationic lipid/DNA ratios (w/w) of DP80-hBMP7 nioplexes 
visualized by agarose electrophoresis. Nioplexes were treated with SDS (lanes 2, 5, 8, 11 and 14) 
and DNase I + SDS (lanes 3, 6, 9, 12 and 15). OC: open circular form, SC: supercoiled form. 
3.3.6. In vitro assessment of osteogenesis 
3.3.6.1. Alkaline Phosphatase (ALP) activity assay 
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As observed in figure 7-A, ALP activity in transfected cell culture was significantly higher whether 
cells were cultured in GM or OM. Although ALP activity of all groups was superior to 
untransfected cells cultured in GM (p < 0.05), no significant differences were discerned among 
those groups (p ˃0.05). 
3.3.6.2. Von Kossa Staining 
After Von Kossa staining, no calcium deposits were observed in the control group (Fig 7-B1). 
However, mineralized bone nodules were observed in D1-MSCs cultured in OM (Fig 7-B2). 
Similar nodules were noticed in culture plates of D1-MSCs transfected with hBMP7, whether 
cultured in GM or OM (Figs 7-B3 and 7-B4, respectively). 
3.3.6.3. Transmission electron microscopy (TEM) 
TEM was applied to detect the ultrastructure of untransfected (7-C1) vs. transfected (7-C2) D1-
MSCs cultured for two weeks in GM. Electron micrographs of both groups showed large 
euchromatic nuclei (N) with prominent nucleoli (n). The chromatin was dispersed except for a thin 
dense layer located immediately inside the nuclear envelope. Although cytoplasmic organelles 
depicted no obvious change, Golgi complex (arrowhead) was evident in many cells of transfected 
group (7-C2). In addition, deposition of amorphous extracellular matrix was noticed (arrows). 
3.4. Discussion 
 Our novel niosomes were formulated with cationic lipid salt (DTPA-HCl) and the non-ionic 
surfactant polysorbate 80 (Fig 1). The cationic lipid, DTPA, has been used for gene delivery 
applications,22 though it was not tested neither in salt form, nor as a niosome formulation. 
Structurally, DTPA-HCl is composed of the four crucial elements that govern the process of gene 
transfection. Namely, the polar head, backbone, linker and two non-polar tails.23During niosome 
elaboration, we endeavored to circumvent the potential cytotoxicity of the ether linker of DTPA-
HCl by decreasing its molar ratio compared to P80 (DTPA-Cl to P80 as 1:2, respectively). 
  Once synthesized, DP80 niosomes showed appropriate nano-scaled size for gene delivery 
purposes. High positive ZP values (> +25 mV) would ensure long-lasting stability24 and 
spontaneous electrostatic interaction with plasmid DNA. Additionally, it could enhance proper  
Chapter 3 
53  
binding of the resulting nioplexes to the negatively charged cell coat prior to nioplexes 
internalization.23 
 
Figure 6: hBMP7 secretion (pg⁄mL) compared to untransfected cells (Ctrl) and TransIT® 2020-
transfected cells (Bars). CCK-8 viability assay (line). Values represent mean ± SD (n = 3). 
Different symbols above bars indicate statistically significant differences. *P < 0.05 compared to 
all data points of line graph. 
To probe the behavior of our niosomes we elaborated, as a proof of concept, DP80-EGFP-
nioplexes by adding pCMS-EGFP reporter plasmid to DP80 niosomes at different cationic 
lipid/DNA mass ratios. Such sequence was adopted to ensure better complex assembly.25 A 
gradual decrease in the size of nioplexes was observed (168 - 84 nm, Fig.2-A), at mass ratios 
studied up to 16/1. Such decline in size is governed by balanced events in a delicate multistep self-
assembly process of complex formation, such as: electrostatic interaction, further membrane 
merging, lipid mixing and aggregate growth.25 The size of nioplexes is of great importance to grant 
proper interactions with cell components (organelle membranes and cytoskeletal filaments). The 
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small size of nioplexes might be advantageous to improve the rate of cellular uptake.26 In addition, 
nioplexes would be able to navigate the mammalian cytoskeleton with mesh size about 200 nm.27 
Regarding the ZP values, the gradual initial increase of superficial charge along with cationic 
lipid/DNA ratios (w/w), followed by a plateau phase, demonstrated the ability of cationic niosomes 
to bind to and neutralize the negatively charged phosphate groups in plasmid DNA.28 At small 
cationic lipid/DNA mass ratios (2/1 and 4/1), the ZP readings were negative and shifted to the 
positive territory (around +20 mV) at 8/1, 12/1, 16/1, and 20/1 mass ratios. At higher ratios, 
nioplexes were figured to function as gene delivery carriers taking advantage of their positive 
surface charge that facilitates proper electrostatic interaction with the anionic glycocalyx during 
the early steps of the endocytosis.29 
The shape of complexes has a marked effect on their performance as a gene delivery candidate,30 
albeit, the effect of particle shape on biological interactions is not yet understood. As reviewed by 
Champion et al,30 vast observations proved the complexity of cell-particle interactions and 
revealed the ability of cells to respond differently to varied particle shapes. For instance, non-
spherical particles were reported to be internalized faster than the perfectly spherical ones.26, 31 
Cryo-TEM micrographs illustrated that most of the DP80-EGFP complexes were not perfectly 
spherical (Fig 2-B). Additionally, the discerned discrete morphology of nioplexes with no 
aggregates (Fig 2-B) could be attributed to the moderately positive surface charge. Interestingly, 
the lamellar pattern observed in several nioplexes is believed to occur during the process of 
complex formation by the complete topological transformation of both lipid and DNA into 
compact quasi-spherical complex particles with diameter around 200 nm, that form string-like 
colloidal aggregates, inside of which, the complexes have an ordered multi-lamellar planar 
structure (Fig 2-B, arrows).32 The regular lamellar spacing of almost 5.5-6 nm (Fig 2-B inset) was 
similar to that reported by LeBihan and colleagues, denoting that the repetitive motif corresponded 
to DNA strands complexed with cationic lipid bilayers.33 
Among other factors that can influence on the transfection process, the electrostatic interactions 
between the negatively charged phosphate groups of DNA and the positively charged amine 
groups of the cationic niosomes merits special attention.20, 28, 34, 35  We observed by agarose gel 
electrophoresis assay that at all cationic lipid/DNA ratios evaluated, niosomes were able to capture, 




Figure 7: Osteogenic differentiation in vitro (A) Validation of ALP activity of the conditioned 
media of D1-MSCs, n=5. * indicated statistically significant differences (P < 0.05). ns indicated 
no statistically significant differences (P ≥ 0.05). (B) Representative light micrographs of D1-
MSCs culture after Von Kossa staining for calcium deposition. Scale bars = 40µm. GM= Growth 
Medium, OM = Osteogenic Medium. (C) TEM micrographs for cell ultrastructure in both 
untransfected (C1) and transfected (C2) cultures. Arrowhead points at Golgi complex, arrows point 
at extracellular matrix deposits. N = nucleus, n= nucleolus. Scale bars = 2 μm. 
 
 Once we evaluated that DP80-EGFP nioplexes would be suitable for gene delivery purposes, 
we proceeded to evaluate their biological performance in vitro. BM-MSCs are of vital importance 
in adult bone repair as they home to the fracture site, proliferate and serve as a source of 
osteochondral progenitors. Hence, bone marrow-derived D1-MSCs were selected for the current 
study. In accordance to our results (Fig 3-A) they were known to represent a multipotent MSC 
platform holding potential of osteogenic fate determination in vitro.36, 37 Moreover, their 
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phenotypic characteristics and osteogenic differentiation potential were reported to be consistent 
with primary human MSCs.36, 38 
 There is a general belief that niosomes are well tolerated both in vitro and in vivo conditions.19 
Our results (Fig 3-B) illustrated that DP80 (16/1) induced transfection efficiency similar to that 
obtained by TransIT® 2020 and L2000 commercial reagents (35.8 %, 40.6% and 35.1%, 
respectively). However, the MFI of the transfected cells (Figs 3-B and 3-C) were significantly 
higher with DP80 (1791 a.u.) compared to TransIT® 2020 (1006 a.u). Interestingly, cell viability 
reported with DP80-EGFP nioplexes was significantly higher than that with L2000, while inferior 
to that reported by TransIT® 2020 commercial reagents. Such cytotoxicity might be induced, even 
in part, by GFP-induced apoptosis that might result from GFP aggregations or free radicals.39 In 
general, the main aim of gene delivery is to attain overexpression of the transfected gene to express 
the protein in super physiological doses. Thereafter, transfection efficiency is not only a matter of 
how many cells were transfected, but also the amount of gene expression by the transfected cells. 
The high transfection efficiency values observed were preceded by a great percentage of nioplexes 
uptake as shown for best transfection efficiency (16/1) (Fig 4-A). Despite the reported high uptake 
percentage (almost 83%), the performance of non-viral vectors is known to be clearly affected by 
their distinct cellular internalization pathway, taking into account the variable effectiveness of 
every pathway in the release of DNA into the cytoplasm, which is one of the critical steps in the 
eventual transgene expression.19 Therefore, we further analyzed intracellular trafficking of our 
nioplexes by blocking three of the most important endocytosis pathways in mammalian cells,26,10 
namely, caveolae-mediated endocytosis (CvME), clathrin-mediated endocytosis (CME) and 
macropinocytosis (MPC). 
 The results observed in figure 4-B suggested that internalization of DP80-EGFP was mainly 
through CvME and CME with no significant difference between them. Although a robust 
consensus does not exist, it is widely accepted that the endolysosomal fate is the hallmark feature 
of CME.40, 41 Oppositely, CvME and/or MPC routes could be advantageous to avoid lysosomal 
degradation, which could ensure a better plasmid delivery and integrity.10,42 Consequently, the 
relevant contribution of the clathrin-mediated endocytosis pathway, which directs nioplexes to the 
lysosomes, could explain the relatively low transfection efficiency values observed (35.8%, Fig 3-
B), despite the fact that high number of cells (83%, Fig 4-A) captured the complexes. 
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The promising results obtained with the reporter EGFP plasmid encouraged us to explore hBMP7 
gene transfection. As done before with DP80-EGFP nioplexes, we characterized DP80-hBMP7 
nioplexes regarding their physicochemical features. As noted in figure 5-A, gradual decline of size 
correlated to the increased cationic lipid/DNA mass ratio (bars). Starting from mass ratio of 4/1, 
ZP values observed were in the positive territory that fluctuated between 18.3 and 26.2 mV. 
Particles were of no perfect shape and mostly acquired the planar lamellar pattern (Fig 5-B). 
Similar to what has been reported in figure 2-C, DP80-hBMP7 nioplexes were able to bind, release 
and protect plasmid DNA against DNase I enzymatic digestion (Fig 5-C). These findings 
suggested that DP80-hBMP7nioplexes could transfect D1-MSCs in vitro. The hBMP7 protein 
secreted after 48 h of transfection (Fig 6) reached its highest value at the ratios of 4-12/1(up to 
1460 pg/ml). These results showed that the mass ratios of best transfection efficiency changed with 
different plasmids used (EGFP at 16/1). 
 The CCK-8 assay interestingly depicted that cells seemed to proliferate more significantly 
when transfection was the best at mass ratios of 8/1 and 12/1. This phenomenon might be due to 
two main factors; first, the negligible cytotoxicity effect of our nioplexes on D1-MSCs at such 
ratios compared to the higher ratios (16/1 and 20/1), and second, a direct enhancement of mitotic 
activity of such cells by the released hBMP7 protein43. 
Although TransIT® 2020 induced significantly efficient transfection (2111.5 pg/ml, Fig. 6), it 
extremely hampered cell viability (23%). This might be referred to the cytotoxic impact of the 
hBMP7- based TransIT® 2020 complexes that seemed to badly attenuate the initial population of 
hBMP7secreting cells.46 Since ELISA assay was performed as early as 48 h post-transfection, 
the number of cells in TransIT® 2020 samples was not obviously enhanced by the putative 
mitogenic effect of hBMP7 protein. 
 Noteworthy that results (shown in figs. 3-B and 6) elucidated the fact that different 
plasmids could behave differently in regard to transfection efficiency or cell viability. In the 
current study, both EGFP and hBMP7 plasmids had a different length (5541 and 4497 bp, 
respectively) and promotors. Therefore, the obtained nioplexes rendered different 
physicochemical characteristics and thus demonstrated discrepant behavior regarding to 
transfection efficiency or cell tolerance. 44,45 
 We further assessed the effectiveness of hBMP7 overexpression to induce osteogenesis 
in vitro using the alkaline phosphatase activity (Fig 7-A). ALP is considered an important 
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parameter to assess osteoblastic phenotype as it is required for mineralization, thus induced early 
during osteoblast differentiation.46 Both ALP assay and Von Kossa staining (Fig 7-B) of the 
mineralized bone nodules denoted that hBMP7 expression induced spontaneous osteoblastic 
differentiation and calcified matrix deposition under standard culture in GM. The amorphous 
extracellular matrix deposition was further shown at the ultrastructural level in figure 7-C2. 
During this process, secreted hBMP7 was anticipated to interact with cell membrane receptors, 
which could induce a signaling cascade that lead to osteoblastic differentiation in autocrine and/or 
paracrine mode.47 Nevertheless, BMP7 transfection did not manifest significant difference when 
cells were cultured in OM for two weeks (Fig 7-B3 vs. 7-B4). 
 Our results suggest that hBMP7-transfected D1-MSCs could be considered not only as an 
effective delivery tool of hBMP7, but also as proliferating and bone forming cells for bone 
regeneration purpose, which offers reasonable hope to use stem cell-based gene delivery by 
niosomes approach to target sites where bone regeneration is needed. To validate that hypothesis, 
additional in vivo experiments and an optimization process of the niosomes formulations would 
be required, since biological conditions are different and not always exists a consistent correlation 
between in vitro and in vivo experiments. 
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Gene transfer to rat cerebral cortex mediated by polysorbate 80 and 
poloxamer 188 nonionic surfactant vesicles 
Abstract 
 
Background: Gene therapy can be an intriguing therapeutic option in wide-ranging neurological 
disorders. Though non-viral gene carriers represent a safer delivery system to their viral 
counterparts, a thorough design of such vehicles is crucial to enhance their transfection properties. 
Purpose: This study evaluated the effects of combined use of two nonionic surfactants, poloxamer 
188 (P) and polysorbate 80 (P80) into nanovesicles–based on 2,3-di(tetradecyloxy)propan-1-
amine cationic lipid (D) – destined for gene delivery to central nervous system cells. 
Methods: Niosome formulations without and with poloxamer 188 (DP80 and DPP80, 
respectively) were prepared by the reverse-phase evaporation technique and characterized in terms 
of size, surface charge, and morphology. After the addition of pCMS-EGFP plasmid, the binding 
efficiency to the niosomes was evaluated in agarose gel electrophoresis assays. Additionally, 
transfection efficiency of complexes was also evaluated in vitro and in vivo conditions. 
Results: In vitro experiments on NT2 cells revealed that the complexes based on a surfactant 
combination (DPP80) enhanced cellular uptake and viability when compared with the DP80 
counterparts. Interestingly, DPP80 complexes showed protein expression in glial cells after 
administration into the cerebral cortices of rats. 
Conclusion: These data provide new insights for glia-centered approach for gene therapy of 
nervous system disorders using cationic nanovesicles, where nonionic surfactants play a pivotal 
role. 
Keywords: gene therapy, non-viral gene vectors, poloxamer 188, niosomes, cationic lipids 
 
4.1. Introduction 
The genetic base of many central nervous system (CNS) diseases along with the recent advances 
in the nanotechnology fields makes gene therapy an attractive therapeutic option.1 Gene therapy 
can improve the quality of life in patients with major brain diseases, including Parkinson, 
Alzheimer, or epilepsy.2–4 Successful delivery of DNA– vector hybrids that can correct such CNS 
disorders was probed.5–7 Although many phase-I clinical trials of CNS gene therapy are 
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documented, only a few have reached phase-II.5 Such modest improvement is due mainly to the 
lack of optimal vehicles able to deliver the genetic material in an efficient way.8 
Being easier in large-scale production with lower production cost, non-immunogenic and non-
oncogenic, non-viral approach offers several advantages in delivering pDNA and siRNA.9,10 
However, their main drawback is the lower transfection efficiency compared with virus-based 
vectors.11 Therefore, further research in the design of such formulations is necessary before they 
become a realistic medical option to treat CNS disorders. 
Among the different available gene delivery systems such as liposomes or micelles, niosomes have 
attracted a great amount of attention.12 Nonionic surfactant lipid vesicles, such as niosomes, are 
synthetic vesicles with high drug-delivery potential.13 Niosomes can deliver both water- and lipid-
soluble molecules. In addition, and depending on their chemical structure, they can also control 
the release of such molecules.14 However, niosomes are more stable and cheaper systems, 
compared with liposomes.15 Among several factors, the nonionic surfactants are known to provide 
stability to the formulation. Other components, such as cationic lipids, can interact with negatively 
charged genetic material to form niocomplexes, in gene delivery context.16,17 
Recently, some encouraging results have been obtained with niosomes based on the hydrochloride 
salt of the cationic lipid 2,3-di(tetradecyloxy)propan-1-amine (DTPA-Cl) and polysorbate 80 
(P80) nonionic surfactant to transfect retinal cells.16 DTPA-Cl is a fairly water-soluble lipid that 
can efficiently condense DNA. In addition, other cationic niosome formulations have been able to 
transfect neuronal cells after intracranial administration in the brain of rats.18 Considering such 
results, we explored the impact of adding poloxamer 188 nonionic surfactant (P) to niosomes that 
contained the hydrochloride salt of cationic lipid DTPA (D) and P80 to obtain two kinds of 
niosomes, with only one surfactant (DP80 formulation) or with a mixture of them (DPP80 
formulation). Previous studies showed that poloxamer 188, a biocompatible copolymer, could be 
well tolerated by cells.19 Moreover, P has been successfully used in several gene-delivery studies 
when combined with different lipid components.20,21  
In addition, other reports in the literature highlight the advantage of combining two surfactants in 
the same formulation.22,23 Particle size, polydispersity index (PDI), and zeta potential (ZP) of both 
niosomes were analyzed for comparison purposes. When the pCMS-EGFP plasmid was added at 
different cationic lipid/DNA ratios (w/w), the resulted nioplexes were physicochemically 
analyzed. In vitro experiments were performed to evaluate the behavior of both vectors in NT2 
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cells regarding their cellular uptake, protein expression efficiency, and cell viability. Afterwards, 
the formulation that showed better results was administered to primary neuronal culture, and then, 
into rat cerebral cortex in order to evaluate protein expression in in vivo conditions. 
4.2. Methods 
4.2.1. Elaboration of cationic niosomes 
 The hydrochloride salt of the cationic lipid DTPA-Cl was synthesized as indicated in 
previous work.24 Once the cationic lipid (D) was produced, it was used to elaborate niosomes that 
were elaborated by modified reverse-phase evaporation technique.25 An amount of 5 mg of D was 
dissolved in 1 mL of dichloromethane organic solvent, and sonicated in 5 mL of surfactant (either 
P80 alone or equal weights of both P and P80). The details of chemical structure of each component 
of the niosome formulations are represented in Figure 1. The emulsions were obtained after a 
sonication process (Branson Sonifier 250®; Branson Ultrasonics Corporation, Danbury, CT, USA) 
at 45 W for 30 seconds. When dichloromethane was evaporated, dispersions of niosome vesicles 
were obtained in the aqueous phase. Then, niosome formulations were named as DP80 and DPP80 
both of them containing DTPA-Cl (D) cationic lipid and P80 or P+P80 as nonionic surfactants at 
a cationic lipid/nonionic surfactant ratio of 1/5 (Table 1). 
 
Table 1 Components (in mg) and physical characterization of niosome formulations regarding 
particle size (nm), PDI, and zeta potential (mV). 
Niosomes Components (mg)  Characterization  
 DTPA Poloxamer 188 Polysorbate 80 Size PDI Zeta potential 
 (D) (P) (P80) (nm)  (mV) 
DP80 5 – 25 54.02±0.94 0.52±0.10 41.9±7.10 
DPP80 5 12.5 12.5 90.41±0.65 0.42±0.01 44.1±4.39 
 
Note: Data represent mean±SD (n=3). 




Figure 1 Chemical structure of: (A) polysorbate 80, (B) poloxamer 188, and (C) cationic lipid 
DTPA. Abbreviation: DTPA, 2,3-di(tetradecyloxy)propan-1-amine. 
 
4.2.2. Plasmid propagation and elaboration of complexes 
The pCMS-EGFP plasmid (5,541 bp; PlasmidFactory, Bielefeld, Germany), was propagated, as 
previously described.14 Nioplexes were obtained after mixing a stock solution of pCMS-EGFP 
plasmids (0.5 mg/mL) with different volumes of suspensions where niosomes were dispersed (1 
mg cationic lipid/mL) to obtain nioplexes at different cationic lipid/DNA ratios (w/w). 
4.2.3. Physicochemical analysis of niosomes and complexes 
The particle size, superficial charge (ZP), and morphology of lipid formulations were analyzed as 
described previously.24,26 To evaluate the interactions between the niosomes and the genetic 
material, an agarose gel electrophoresis assay was performed.24 
4.2.4. In vitro transfection in NT2 cells 
NT2 cells (ATCC®−CRL, 1973) were cultivated and processed as previously described.27 Cells 
were exposed to complexes (1.25 µg of pCMS-EGFP/well). After 4 hours of incubation, 
transfection medium was removed and refreshed with complete medium. Cells were allowed to 
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grow for 24 hours until being analyzed by fluorescence microscopy (EclipseTE2000-S; Nikon 
Instruments, Melville, NY, USA) and flow cytometry (FACSCalibur; BD, San Jose, CA, USA) as 
described previously.14 Positive control (Lipofectamine® 2000 [L2K], Gibco®; Life Technologies 
S.A., Madrid, Spain) was prepared following the manufacturer’s protocol. 
4.2.5. Cellular uptake and intracellular disposition of complexes 
NT2 cells were cultured as previously mentioned in Section “In vitro transfection in NT2 cells.” 
After 4 hours of incubation with complexes, the transfection medium was removed and cells were 
washed thoroughly with PBS, trypsinized, and analyzed by FACSCalibur flow cytometer to 
evaluate cellular uptake. In total, 10,000 events were collected and analyzed for each sample. Each 
sample was analyzed in triplicate. 
The intracellular distributions of the complexes were analyzed by confocal laser scanning 
microscopy (CLSM, Olympus Fluoview 500). Specific fluorescence-labeled commercial reagents 
were used to evaluate co-localization with Fluorescein isothiocyanate (FITC)-pCMS-EGFP 
plasmid by Mander’s co-localization coefficient (M) as previously reported.27 
4.2.6. Primary cortical neuron culture 
Experimental procedures for in vitro isolation and culture of primary cortex cells were carried out 
according to the directive 2010/63/EU of the European Parliament and of the Council, and the RD 
53/2013 Spanish regulation on the protection of animals use for scientific purposes. Additionally, 
all procedures were approved by the Miguel Hernandez University Committee for Animal Use in 
Laboratory. Dissociated cultures of primary cortical neurons were obtained from E17–E18 rat 
embryos (Sprague–Dawley) and preserved in Hanks’ Balanced Salt Solution during extraction. 
Then, trypsin was added to the medium and incubated at 37°C for chemical dissociation. 
Subsequently, the tissue was dissociated in neurobasal medium/FBS and cell density was 
determined using a hemocytometer. Cells were seeded on glass coverslips following the same 
transfection protocol previously described for cellular uptake and trafficking studies. Then, the 
samples were incubated overnight at 4°C with the primary antibodies and rabbit anti-glial fibrillary 
acidic protein (GFAP) (1:300), as a marker of glial cells and mouse anti-GFP (1:100) diluted in 
PBS containing TritonX100 (0.5%). Later, coverslips were washed in PBS and incubated for 1 
hour with specific Alexa Fluor 555 and Alexa Fluor 488 conjugated secondary antibodies (Thermo 
Fisher Scientific, Madrid, Spain). Hoechst 33342 was used to label the nuclei. Finally, coverslips 
were mounted for imaging and analyzed with a Leica TCS SPE fluorescence microscope. 
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4.2.7. In vivo studies in rat brain 
Adult male Sprague–Dawley rats were used for in vivo experiments. All procedures were carried 
out in accordance with the Spanish and European Union regulations for the use of animals in 
research and supervised by the Miguel Hernandez University Standing Committee for Animal Use 
in Laboratory. Pretreatment of rats and injection of the complexes were performed as previously 
reported.18 
4.2.8. Analysis of protein expression in brain 
About 72 hours after surgery, animals were sacrificed and perfusion with PBS followed by 
paraformaldehyde (4%) was performed for fixation. Then, rat brains were preserved in 
paraformaldehyde (4%) and cryoprotected in sucrose solution (30%) with PBS before slicing. A 
cryostat (HM 550; Microm International GmbH, Walldorf, Germany) was used to obtain slices of 
20 µm from coronal frozen sections close to the area of injection. Next, slices were mounted for 
immunohistochemistry analysis with rabbit anti-NeuN (1:100) to label neurons and with mouse 
anti-GFP (1:100) diluted in PBS containing TritonX100 (0.5%) and incubated at 4°C over-night. 
Thereafter, slices were washed in PBS and incubated for 1 hour in dark with specific Alexa Fluor 
555 and Alexa Fluor 488 conjugated secondary antibodies for visualization. Nuclei were 
counterstained with Hoechst 33342.18 
4.2.9. Statistical analysis 
Statistical differences between groups at significance levels of .95% were calculated by ANOVA 
and Student’s t-test. In all cases, P-values ,0.05 were regarded as significant. Normal distribution 
of samples was assessed by the Kolmogorov–Smirnov test and the homogeneity of the variance 
by the Levene test. Numerical data were presented as mean±SD. 
4.3. Results 
4.3.1. Physicochemical characterization of niosomes/complexes 
Table 1 shows the characterization of both DP80 and DPP80 niosome formulations. The niosomes 
prepared only with P80 (DP80) had sizes around 54 nm. Interestingly, when equal weights of both 
tensioactives, P and P80, were incorporated, the size obtained was significantly larger (90.4 nm) 
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with a slight decrease in PDI (0.42, instead of 0.52). Regarding the surface charge, all niosomes 
were in the positive territory ranging from 42 to 44 mV. 
 
Figure 2 characterization of DP80 and DPP80 complexes. Notes: (A) Particle size (nm) and ZP 
(mV). The data represent mean±SD (n=3). (B1, B2) Cryo-TEM pictures of nioplexes. Arrows in 
both insets point to the multi-lamellar pattern. (C) agarose gel electrophoresis assay at different 
cationic lipid/DNA ratios of DP80 and DPP80 complexes (upper and lower panels, respectively), 
based on both formulations. lanes are shown as: 1–3, uncomplexed DNA; 4–6, mass ratio 2/1; 7–
9, mass ratio 4/1; 10–12, mass ratio 6/1; and 13–15, mass ratio 8/1. lanes 2, 5, 8, 11, and 14 depict 
niocomplexes treated with SDS, while lanes 3, 6, 9, 12, and 15 were treated with DNase I+ SDS. 
OC and SC (open circular and supercoiled forms, respectively). Abbreviations: SDS, sodium 
dodecyl sulphate; ZP, zeta potential. 
 
Figure 2 summarizes some parameters of DP80 and DPP80 complexes in terms of size, superficial 
charge (ZP), morphology, and plasmid-binding capacity. DPP80 complexes depicted sizes larger 
than DP80 (P,0.05), except for 12/1 ratio (where no true difference was noticed, P.0.05). For both 
formulations, complexes gradually tended to decrease in size while ratio increased. In general, 
values of size/charge were significantly affected by the DNA incorporated into these complexes. 
Starting with the mass ratio of 2/1, the sizes of DP80 and DPP80 complexes were around 168 and 
219 nm, respectively. A gradual reduction was discerned to become almost 106 and 111 nm at 
12/1 ratio. The PDI values of both nioplexes were around 0.2 (as depicted in Table S1). Regarding 
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ZP of DP80 complexes (Figure 2A, lines), it started with negative values at 2/1 and 4/1 ratios (−29 
and −14 mV, respectively) which gradually increased towards the positive territory to remain 
around +20 mV. The behavior of DPP80 complexes was different. In this case, all ZP values were 
positive. In addition, ZP values increased from 20 mV at 2/1 ratio to 32.5 mV at 8/1 ratio, then 
decreased in the last two ratios (10/1 and 12/1) (Figure 2A). When assessed by cryo-TEM (Figure 
2B), both DP80 and DPP80 complexes at 6/1 (w/w) ratio appeared as electron dense particles with 
a discrete distribution. Interestingly, DPP80 (Figure 2B3) depicted less tendency to form 
aggregates compared with DP80 (Figure 2B1). At a higher magnification (Figure 2B2 and B4), 
complexes were mostly elongated with a lamellar morphology (arrows). Agarose gel 
electrophoresis assays (Figure 2C) revealed the capacity of DP80 niosomes to bind efficiently to 
DNA (lanes 4, 7, 10, and 13 that corresponded to 2/1, 4/1, 6/1, and 8/1 ratios, respectively). On 
the other hand, the ability of DPP80 niosomes to capture DNA increased proportionally with the 
increase in the ratio (Figure 2C). Upon addition of sodium dodecyl sulphate (SDS) the DNA bound 
to the niosomes was released from all studied complexes. The absence of white bands in wells 5, 
8, 11, and 14 (2/1, 4/1, 6/1, and 8/1 ratios) confirmed this fact. Interestingly, the supercoiled (SC) 
bands observed in lanes 6, 9, 12, and 15 (Figure 2C, lower panel) confirmed that the plasmid DNA 
released from the DPP80 niosome formulation was protected from degradation at all ratios tested. 
However, DP80-released DNA was not protected at ratios of 2/1 and 4/1 (Figure 2C, upper panel). 
4.3.2. Protein expression and viability studies 
Figure 3A shows a peak of 28.8% of transfected cells when DP80 was used at 6/1 mass ratio. 
Regarding DPP80 formulation, the best transfection percentage (30.1%) was observed again at 6/1 
mass ratio, followed by a gradual decline. No protein expression was observed on cells when free 
“uncomplexed” DNA was analyzed (data not shown). The viability of transfected cells (Figure 
3A, lines) depicted a clear negative relationship with the cationic lipid/DNA mass ratio. DPP80 
(dashed line) showed higher cell viability results compared with DP80 formulation (continuous 
line) at all ratios studied, unless at 2/1 ratio, where cell viability was around 100% in both 
formulations. At 6/1 ratio, cell viability value was 85.4%, significantly higher (P,0.05) than that 
of DP80 at the same 6/1 ratio and Lipofectamine 2000 positive control (80.4% and 80%, 
respectively). Figure 3B2–B4 revealed fluorescence overlay and phase contrast micrographs of 
NT2 cells at 24 hours post-transfection of both formulations at 6/1 ratios as well as L2K positive 
control. In all cases, NT2 cells retained their normal morphology compared with the untransfected 
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(control [Ctrl]) cells (Figure 3B1). Mean fluorescence intensity (MFI) of cells transfected by 
complexes based on DPP80 niosomes at a ratio of 6/1 had markedly higher values (P,0.05) 
compared with those obtained by complexes based on DP80 niosomes (Figure 3C). 
Figure 3 Transfection studies in NT2 culture cells.  
Notes: (A) Flow cytometry analysis of percentage of cells that express EGFP (bars) and percentage 
of live cells (lines) at different cationic lipid/DNA ratios (w/w). Values represent mean±SD (n=3). 
*P,0.05 compared with DP80 at 6/1 and L2K at 2/1. Overlay of fluorescence and DIC pictures of 
control cells (B1), DP80 at 6/1 (B2), DPP80 at 6/1 (B3), and L2K at 2/1 mass ratios (B4). scale 
bars=100 µm. (C) Mean fluorescence intensity (a.u.). Abbreviations: a.u., arbitrary unit; ctrl, 
control; DIC, digital image correlation; L2K, lipofectamine® 2000. 
 
4.3.3. Trafficking studies 
Both FITC-labeled complexes were applied at the cationic lipid/DNA (w/w) mass ratio that 
depicted the best transfection percentage (6/1; as shown in Figure 3A). With an uptake percentage 
of about 95%, DPP80 complexes exceeded the other two formulations (DP80 and L2K of 84% 
and 85%, respectively). Control cells transfected with DNA alone did not show any uptake (Figure 
4A and B1). However, when FITC-labeled DP80 and DPP80 complexes were used, some 
fluorescence signal within the cytoplasm of most of the cells in the field was observed, as shown 
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in Figure 4B2 and B3. The internalization studies of FITC-labeled DPP80 complexes at 6/1 ratio 
are represented in figure 4. At 4 hours after incubation of FITC-labeled complexes with 
fluorescence markers of CME [(clathrin mediated endocytosis); AlexaFluor 546-Transferrin; 
Figure 4C1], CvME [(caveolae mediated endocytosis); AlexaFluor 555-Cholera Toxin; Figure 
4C2], MPC ([macropinocytosis]; AlexaFluor 594-Dextran;Figure 4C3), and late 
endosome/lysosome(LysoTracker red DND-99; Figure 4C4), Mander’s M1 co-localization 
coefficient was 0.39, 0.88, 0.75, 0.81, respectively. 
Figure 4 Trafficking studies in NT2 culture cells. Notes: (A) Flow cytometry measurement of the 
percentage of cells that captured plasmid labeled with FITC. error bars represent SD (n=3). *P,0.05 
compared with other groups. (B1–B3) Fluorescence micrographs with FITC-labeled naked 
plasmids, and DP80 and DPP80 niocomplexes (at 6/1 mass ratios), respectively (scale bar=25 µm). 
(C) confocal micrographs showing intracellular distribution of DPP80 complexes, where plasmid 
is labeled in green color, and AlexaFluor 546-Transferrin (C1), AlexaFluor 555-Cholera Toxin 
(C2), AlexaFluor 594-Dextran (C3), and LysoTracker red DND-99 markers (C4), all in red. Nuclei 
of cells were stained with DAPI-fluoromount G (blue) (scale bar=25 µm). Abbreviations: CME, 
clathrin mediated endocytosis; CvME, caveolae mediated endocytosis; FITC, fluorescein 
isothiocyanate; M, Mander’s co-localization coefficient; MPC, macropinocytosis.  
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4.3.4. Protein expression in primary cortical neuron and rat brain 
Protein expression was observed in primary cortical cultures of cells transfected with DPP80 
complexes at 6/1 ratio (w/w) and is shown in Figure 5A1. In any case, none of those cells were 
GFAP+ve (Figure 5A2). Interestingly, 72 hours after intracortical administration of complexes, 
NeuN−ve (non-neuronal) positive cells with glial morphology were observed expressing EGFP in 
their dendrites (Figure 5B). Other pictures of brain experimented with different injections and the 
corresponding contralateral sections are shown in Figure S1. 
4.4. Discussion 
Considering the recently shown promising results of cationic niosomes to transfect stem cells17 and 
neurons in both brain and retina,18,28 and the reports on literature that highlights the benefits of 
combining two surfactants in the same formulation,22,23 we explored in the present manuscript, the 
impact of combining P and P80 nonionic surfactants in the same niosome gene-delivery system 
based on the cationic lipid DTPA. 
Our data showed that a particle was affected depending on the type of surfactant used (Table 1). 
The difference in size could be due to the different hydrophilic–lipophilic balance (HLB) value of 
surfactant used. P80 (lower HLB value) gave rise to nanovesicles of smaller sizes.29 However, the 
interaction between surfactant(s) and cationic lipid in niosomes should not be excluded as another 
influential factor that could also affect the vesicle size.30 
Prior to performing transfection experiments, we characterized complexes at different mass ratios 
of cationic lipid and DNA content (Figure 2). There is no general rule in the scientific community 
about the optimal size of non-viral vector particles for gene-delivery applications. In any case, it 
is clear that this parameter affects their transfection efficiency,31 and in the case of niosome 
vesicles, it strongly depends on the mass ratio between both the cationic lipid and the DNA. As 
can be observed in Figure 2A, when DNA was bound to obtain both DP80 and DPP80 nioplexes 
at 2/1 ratio, the size exceeded 150 and 200 nm, respectively. In any case, when the ratio increased, 
the size of nioplexes decreased, probably due to the condensation of DNA plasmid on the surface 
of niosome vesicles in a more efficient multi-lamellar pattern by interaction between opposite 
charges, as discerned in the cryo-TEM examination (Figure 2B2 and B4, arrows). The shape of 
complexes has a marked effect on their final performance as a gene-delivery carrier.32 
Interestingly, the lamellar pattern discerned in several complexes is believed to occur during the 
process of complex formation. The complete topological transformation of both lipid and DNA 
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into complex particles would form string-like aggregates, in which complexes have a multi-
lamellar pattern. The discrete morphology of complexes at 6/1 mass ratio (Figure 2B) could be 
attributed to the moderately positive surface charge (20 mV).16 DPP80 complexes had a higher ZP 
(30 mV), and thus depicted less aggregates as they tend to repel each other.33 Another crucial 
parameter that influences the transfection process is the electrostatic interactions between the 
negatively charged phosphate groups of DNA and the positively charged amine groups of the 
cationic niosomes.34 Such parameter was analyzed in agarose gel electrophoresis assays (Figure 
2C). For DPP80 niosomes, all ratios analyzed released and protected plasmid DNA against 
degradation. However, complexes based on DP80 niosomes (Figure 2C, upper panel) failed clearly 
to protect the DNA at low cationic lipid/DNA rates. Despite the fact that DP80 niosomes 
condensed and released properly the DNA after the addition of SDS at all analyzed mass ratios, 
the protective capacity of DNA against enzymatic digestion is a mandatory issue for efficient gene-
delivery vectors. We hypothesize that electrostatic interactions between the DP80 niosomes and 
DNA at low cationic lipid/DNA ratios (2/1 and 4/1) were efficient to condense the DNA, but were 
not strong enough to protect the DNA,24 that might be attributed to the net negative surface charge 
of the complexes at the aforementioned ratios. 
Afterward, both complexes were evaluated in vitro conditions to analyze protein expression and 
cytotoxic effect of formulations in NT2 culture cells. This cell line has been reported to be a 
promising human cell source for in vivo therapeutic application in many CNS disorders.35,36 Their 
therapeutic importance lies in the fact that, following retinoic acid treatment, NT2 cells undergo 
an irreversible commitment to terminally differentiate into stable post-mitotic neurons, even long 
time after transplantation in animal brain.37 Moreover, NT2-mediated functional recovery in 
preclinical stroke models has endorsed their application in clinical trials.38 NT2 cells are stable, 
easy to cultivate, amenable to scale-up for cell production, and represent a CNS-like delivery 
vehicle for glioblastoma therapy.38–40 NT2 cells can be differentiated into both neuronal and glial 
cells.41 Therefore, these cells represent an appealing model to evaluate transfection efficiency by 
non-viral vectors based on cationic niosomes. 
The data of transfection efficiency (Figure 3A) revealed the impact of the surfactant included in 
the formulation. When DP80 was used, the values of transfection started to increase at the 6/1 
mass. Complexes at the lower ratios (2/1 and 4/1) had previously shown an inability to protect 
DNA against enzymatic digestion (Figure 2C), which could justify low transfection efficiencies at 
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these ratios. However, the incorporation of P in DPP80 formulation markedly enhanced 
transfection at the lower ratios (2/1 and 4/1) and maintained sufficient transfection at the higher 
ratios. The addition of P in DPP80 complexes shifted the ZP (Figure 2A) from negative to positive 
values at small mass ratios (2/1 and 4/1), which would enhance uptake, and thus transfection 
(Figure 3A).42 Interestingly, DPP80 depicted higher MFI compared with DP80 at the cationic 
lipid/DNA mass ratio of 6/1 (maximum transfection). Actually, one of the most relevant concerns 
of gene therapy is to attain enough expression of the protein to reach physiological levels. Thus, 
the amount of protein expression by the transfected cells needs to be also considered along with 
the percentage of transfected cells when designing non-viral vectors for gene-delivery purposes.26 
Regarding cell viability, DPP80 niosomes showed less toxic effect on NT2 cells than DP80 
counterpart at all mass ratios analyzed, being cell viability at 6/1 mass ratio significantly superior 
to that reported by liposome-based L2K transfection reagent. These promising data encouraged us 
to perform further in vivo studies, where not only gene-delivery efficiency but also cytotoxicity 
needs to be considered. The higher cationic lipid/DNA mass ratios resulted in a clear toxic effect 
on cells which were more accused in the case of DP80 niosomes, without the increase of 
transfection efficiency. 
The fact that both the type of surfactant and the amount of such surfactant influence the biological 
function of nano-vesicles 43 could explain the low percentage of transfected cells and viability 
results observed when only P (Figure S2) or P80 (Figure 3A) surfactant was used in niosome 
formulations (DP and DP80, respectively). Additionally, when liposome vesicles were elaborated 
in the absence of any kind of surfactant (referred to as D; Figure S2), both transfection efficiency 
and cell viability values were also lower than the values obtained with DPP80 niosomes. To 
analyze more deeply the complex transfection mechanism of DPP80 complexes in NT2 culture 
cells, we performed some trafficking studies to investigate both the cellular uptake of complexes 
and the posterior cytoplasmic disposition inside the cells, since it has been previously reported on 
the literature that those parameters could markedly influence the gene-delivery properties of 
vectors.14 Cellular uptake values were compared with DP80 niosomes as well as L2K transfection 
reagent. As can be observed in Figure 4A, the uptake of DPP80 complexes exceeded that of their 
DP80 counterparts that could be due to their higher surface charge (Figure 2A) or to more specific 
interactions of such nioplexes with some lipid components present on the cell membrane.44 
Additionally, it has been reported that variations in the length of surfactant carbon chains and/or 
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in the number of unsaturated bonds (inside their carbon chains) can affect the permeability of 
nanovesicles across membranes.29 However, the great difference observed on DPP80 complexes 
between cellular uptake (95%; Figure 4A) and percentage of transfected cells (30%; Figure 3A) 
suggests that other biological processes involved on the transfection process should also be 
evaluated.45 Therefore, we analyzed as well the endocytosis mechanism and the co-localization 
with the late endosome. Despite the absence of consensus on the most efficient endocytosis 
pathway, we analyzed the endocytosis processes mediated by clathrin, caveolae, and 
macropinocytosis, which could affect the fate of internalized complexes.46 
The observed results in Figure 4C suggested that internalization of DPP80 complexes was 
mediated, mainly by caveolae and macropinocytosis. Such endocytosis pathways, normally, are 
connected with the lysosomes. In such compartments, the acid pH value, normally, degrades the 
genetic material, which in turn could reduce the percentage of transfected cells.45 Therefore, the 
co-localization of complexes with the late endosome/lysosome (Figure 4C4) could explain why 
out of 95% of NT2 that captured DPP80 complexes (Figure 4A), only around 30% of them were 
successful to eventually express EGFP (Figure 3).47 
Next, and before proceeding for in vivo studies in rat brain, we analyzed the transfection efficiency 
of DPP80 complexes in primary cortical cultures of rat embryos, where different kinds of neurons 
and glial cells are interconnected to set up complex neuronal–glial networks. Results showed some 
positive EGFP cells (Figure 5A1). Next, the lack of GFAP+ve reactivity in immunohistochemical 
assays confirmed that such EGFP-positive cells could be neurons (Figure 5A2). After observing 
these promising results obtained in neurons, we proceeded to evaluate in rat brain the protein 
expression of DPP80 complexes after intracranial injection. We did not observe any sign of 
toxicity in the cortical tissue after injection (data not shown). Unlike the primary culture 
observations, the NeuN−ve cells (neuroglia) were the only transfected cells (Figure 5B). The 
discrepancies between in vitro and in vivo assays are widely recognized and could be probably due 
to the fundamental difference in the mechanism of gene delivery in both biological contexts.48 
The preference of DPP80 complexes to transfect mainly glial cells instead of neurons could be 
explained by the fact that glial cells have a higher mitotic and phagocytic activity.49 Therefore, 




Figure 5 EGFP gene expression in primary neuronal cell cultures (A1 and A2). GFAP+ve neuroglia 
(red) and nuclei were stained in blue color with Hoechst 33342 (scale bars=40 and 20 µm, 
respectively). (B) in vivo expression green protein (scale bar=40 µm). Note: nuclei are shown in 
blue color (Hoechst), while neurons in red (neuN+ve). 
 
By contrast, the lack of protein expression observed in neurons of rat cortex exposed to DPP80 
complexes could be explained by the particular biological processes of these kind of cells where 
both endocytosis and posterior intracellular disposition are severely hampered.50 Considering these 
encouraging in vivo results, DPP80 complexes could be used as non-viral vectors to deliver genetic 
material into glial cells in the CNS, in order to tackle neurological disorders that affect these kind 
of cells.51 Alterations of glial cells are commonly found in many devastating neurological 
disorders such as Alzheimer and Parkinson, to name just the most relevant ones.51,52 
4.5. Conclusion 
Our results showed that physicochemically characterized DPP80 niosomes elaborated with a 
mixture of both P and P80 nonionic surfactants were able to transfect efficiently NT2 cells without 
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compromising their viability after cellular uptake mainly mediated by CME and MPC. Such novel 
biocompatible nanocarriers were able to induce in vivo transfection into glial cells of rats after 
intracortical administration. Interestingly, DPP80 gene carriers not only represent a promising tool 
for direct in vivo transfection, but also for cell-based gene delivery applications, since transfected 
NT2 cells or their derived neurons could be used as a delivery tool of therapeutic genes for different 
neurologic disorders.53,54 
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4.8. Supplementary materials 
Table S1 Polydispersity index (PDI) of DP80 and DPP80 niocomplexes at different cationic 
lipid/DNA mass ratios. 
Nioplexes 2/1 4/1 6/1 8/1 10/1 12/1 
DP80 0.296±0.016 0.222±0.014 0.211±0.013 0.193±0.020 0.229±0.009 0.234±0.012 
DPP80 0.208±0.031 0.211±0.017 0.230±0.014 0.217±0.003 0.258±0.032 0.202±0.005 
Note: Data represent mean±SD (n=3). 
 
Figure S1 (A) EGFP expression in rat cortex. nuclei are shown in blue (Hoechst); scale bar=40 
µm. (B) contralateral picture. nuclei are shown in blue (Hoechst), and neurons in red (neuN+ve); 





Figure S2 (A) Transfection efficiency of D liposomes and DP niosomes in NT2 cells. Percentages 
of cells that express green protein (bars) and live cells (lines). Values represent mean±SD (n=3). 
(B1 and B2) Overlay of fluorescence and DIC pictures of NT2 cells with D liposomes (6/1) and 
DP niosomes (2/1), respectively (scale bar=100 µm). Abbreviations: DIC, digital image 
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Cationic niosome-based hBMP7 gene transfection of neuronal 
precursor NT2 cells to reduce the migration of glioma cells in vitro 
 
ABSTRACT 
This study explores interesting complementary approaches in cell-based hBMP7 gene delivery in 
order to mitigate the migration of glioblastoma cells based on the idea that this human bone 
morphogenetic protein (hBMP7) has enormous therapeutic potential in curing brain injuries as 
well as malignancies. After physicochemical characterization, the non-viral cationic niosomes 
were complexed with pUNO1-hBMP7 plasmids and used to transfect neuronal precursor NT2 
cells. Subsequently, the transfected cells were co-cultured with glioma C6 cells to determine their 
antitumor effect in vitro. However, the co-culture with either untransfected/transfected NT2 cells 
may reduce the viability of C6 glioma cells, the hBMP7-overexpressing NT2 cells hamper the 
migration of C6 glioma cells. These results highlight the potential of NT2 cell-based delivery of 
hBMP7 for impeding the metastasis of glioma cells. 
 
Key words: Glioblastoma; Gene therapy; hBMP7; Niosomes; NT2 cells 
 
5.1. Introduction 
Glioblastoma multiforme (GBM), the most aggressive primary intracranial tumor, is well-known 
for its high mortality rate and poor treatment outcomes [1]. The average survival time of patients 
following surgery combined with chemotherapy and/or radiotherapy, is less than 12 months. 
Therefore, therapeutic approaches are still needed to fight this devastating disease. During glioma 
genesis, the tumor-suppressive activity of transforming growth factor-β (TGF-β) signaling 
pathway is generally perturbed, leading to malignant progression [2]. 
The human bone morphogenetic protein 7 (hBMP7), a member of the transforming growth factor 
β superfamily, plays a pivotal role in the development of bone, kidney and nervous tissues [3]. 
Interestingly, exposure to BMP7 can induce canonical BMP signaling in stem-like glioblastoma 
cells, in vitro [4]. The ability of BMP7 to induce the differentiation of brain tumor stem cells is 
accompanied by the attenuation of stem-like marker expression and reduction of self-renewal. 
Currently, the in vivo delivery methods of BMP7 are basically through multiple local and/or 
intravenous injections of the recombinant hBMP7. Unlike some other growth factors, BMPs have 
a short half-life, are not particularly soluble and seem to act locally, so the aforementioned delivery 
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routes are often ineffective [5], and need multiple injections. Nevertheless, in sensitive tissues such 
as brain tissue, repeated injections could lead to inevitable tissue damage. Therefore, alternative 
approaches for supplying BMP7 to glioma cells are needed to circumvent the negative aspects of 
conventional therapies. Amongst those promising alternatives are those based on cell/gene 
delivery. More specifically, human neuronal precursor NT2 cells exhibit two ideal characteristics 
for cancer gene therapy; they have tumor-selective migratory capacity and they can be genetically 
manipulated to express selected therapeutic genes [6]. 
As gene delivery systems, non-viral vectors have gained attention over the years, in comparison 
to their counterparts, the viral-based vectors [7,8]. Non-viral gene carriers are not as limited by the 
size of the transferred genes and they have a lower immunogenicity and oncogenic profile. These 
appealing features make the non-viral gene carriers potential candidates for commercialization be-
cause of how easy it is to produce them and also because there are less hurdles to overcome in 
terms of meeting the regulatory standards. 
As non-viral gene carriers, cationic niosomes are osmotically active self-assembled vesicles made 
up of cationic lipids and non-ionic surfactants. They are better than liposomes in terms of cost 
effectiveness and chemical stability, and have received increasing attention over time as potential 
gene delivery vehicles [9,10]. 
In our recent study [11], we developed a novel cationic niosome gene carrier based on chemical 
compounds (the cationic lipid 2,3-di-tetradecyloxypropan-1amine, the non-ionic surfactants 
poloxamer 188 and polysorbate 80) demonstrating flattering properties for gene delivery 
applications [12]. Our previous results obtained with reporter GFP plasmids, in vitro/vivo, have 
encouraged us to proceed with the current study in which we aimed to provide a proof-of-concept 
of whether NT2 cells could be used as a model for hBMP7 gene expression in order to combat 
glioma cell migration. We initially transfected NT2 cells with DPP80- hBMP7 nioplexes and then 
we investigated their potential “combined” antitumor effect on C6 glioma cell line, in vitro. 
5.2. Material and methods 
 
5.2.1. Material 
Human teratocarcinoma NTERA2/D1(NT2) (ATCC®−CRL, 1973) and the rat glioma cell line 
(C6, CCL-107) were purchased from the American Type Culture Collection (ATCC, Manassas, 
VA, USA). C6 cells were grown in the ATCC-formulated F-12K Medium (Catalog No. 30-2004). 
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Dulbecco's Modified Eagle's Medium (DMEM, ATCC 30 −2002), trypsin, Fetal bovine Serum 
(FBS) were purchased from Gibco® (San Diego, California, US). Opti-MEM® reduced medium, 
Lipofectamine® 2000 transfection reagent, antibiotics [100 U/ml penicillin and 100 μg/ ml 
streptomycin (Pen/Strep)] were acquired from Gibco® (Life Technologies S.A., Madrid, Spain). 
Cell counting (CCK-8) viability/ proliferation assay and crystal violet were obtained from Sigma 
Aldrich (Madrid, Spain). GelRed® solution was obtained from Biotium (Hayward, California, 
USA), while other materials for gel electrophoresis were obtained from Bio-Rad (Madrid, Spain). 
pUNO1-hBMP7 plasmid (0.5 mg/ml) was obtained from InvivoGen (Toulouse, France). Sodium 
dodecyl sulfate (SDS), DNase I, polysorbate 80, poloxamer 188, and PBS were purchased from 
Sigma Aldrich (Madrid, Spain). Uncoated Transwell® 24 well microplates with 8.0 μm pore size 
(Costar-Corning, Corning, NY). 
5.2.2. Preparation of niosome vesicles 
The cationic lipid 2,3-di (tetradecyloxy)propan-1-amine hydrochloride (D) was synthesized by 
slightly modifying the experimental protocol previously described [13]. Afterward, niosomes were 
manufactured by modifying the reverse phase evaporation technique as discussed earlier [14]. 
Briefly, the cationic lipid (5 mg) was dissolved in dichloromethane (1 ml), and then emulsified in 
5 ml of non-ionic surfactant “equal weight % of polysorbate 80 (P80) and poloxamer 188 (P). The 
emulsion was obtained by sonication (Branson Sonifier 250®, Branson Ultrasonics Corporation, 
Danbury, USA) at 45 W for 30 s. After evaporating the dichloromethane, the resulting niosomes 
were referred to as DPP80 (components shown in Fig. 1). 
5.2.3. Preparation of DPP80-hBMP7 nioplexes 
The niosome/DNA complexes (nioplexes) were obtained by mixing an appropriate volume of a 
stock solution of pUNO1-hBMP7 plasmid (0.5 mg/ml) with different volumes of niosome 
suspensions (1 mg cationic lipid/ml) in order to obtain different cationic lipid/DNA ratios (w/w). 
The mixture was incubated for 30 min at room temperature to ensure electrostatic interactions. 
5.2.4. Assessment of DPP80-hBMP7 nioplexes’ features 
Dynamic light scattering (DLS) and Laser Doppler Velocimetry (LDV) (Zetasizer Nano ZS, 
Malvern Instruments, UK) were used to determine the particle size and zeta potential (ZP), 
respectively. Particle size was obtained using cumulative analysis where all measurements were 




Fig. 1. Chemical structure of: A) Poloxamer 188 (P), B) Polysorbate 80 (P80), and C) Cationic 
lipid [2,3-di(tetradecyloxy)propan-1-amine] (D). 
 
Nioplexes were examined by via cryo-TEM (TECNAI G2 20 TWIN), operating at an accelerated 
voltage of 200 KeV in a bright-field and low-dose image mode [15]. The acquired digital images 
were used to assess the nioplexes' morphology. The niosomes’ potential to condense, liberate and 
protect the pUNO1-hBMP7 plasmid DNA against enzymatic digestion was evaluated using an 
agarose gel retardation assay. The naked and niosome-complexed DNA samples (200 ng of 
plasmid/20 μl) were run on an agarose gel (0.8% w/v). The tris–acetate–EDTA buffer-immersed 
gel was later exposed to 120 V for 30 min. In order to analyze the release of DNA from nioplexes 
at different cationic lipid/DNA mass ratios, 20 μl of the SDS solution (2%) were added/sample. 
The supposed nioplexes-induced protection for DNA against DNase I enzymatic digestion was 
assessed by adding 1U DNase I/2.5 μg DNA. Subsequently, mixtures were incubated at 37 °C for 
30 min followed by adding an SDS solution (like above) to release DNA from the nioplexes. The 
resulting bands were stained with GelRed™ and visualized by ChemiDoc™ MP Imaging System 




Fig. 2. A) Particle size (nm) and Zeta potential (mV). Data represent mean ± SD (n = 3). B) Cryo-
TEM micrographs of nioplexes at 6/1 cationic lipid/DNA mass ratio. Scale bar 500 nm (inset, 100 
nm). C) Gel retardation assay of nioplexes. Lanes 2, 5, 8, 11 and 14 depict nioplexes treated with 
SDS, while lanes 3, 6, 9, 12 and 15 correspond to DNase I- and SDS-treated nioplexes. OC and 
SC: open circular and supercoiled forms, respectively. 
 
5.2.5. In vitro culture and transfection of NT2 cells 
NT2 cells (ATCC®−CRL, 1973) were cultured in a growth medium composed of; Dulbecco's 
Modified Eagle's Medium (DMEM), 10% fetal bovine serum (FBS) and antibiotics (100 U/ml 
penicillin and 100 μg/ml streptomycin. The night before transfection, NT2 cells were seeded in 
24-well plates at an initial density of 8 × 104 cells/well and allowed to proliferate up to 70−80% 
confluence. The medium was then replaced with serum-free Opti-MEM, and cells were exposed 
to the nioplexes at a concentration of 1.25 μg of pUNO1-hBMP7/well. After 4 h of incubation, the 
serum-free transfection medium was replaced with the growth medium. 24 h later, conditioned 
media (NT2-CM) was collected, filtered (0.22 μm filters) and preserved at −80 °C until ELISA 
was performed to determine the hBMP7 secreted. Cell counting (CCK-8) viability/proliferation 
assay was carried out as previously reported [16]. The color development was read at 450 nm 
(Tecan M200 microplate reader), corrected with reference wavelength at 690 nm, and normalized 
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against blank wells. The positive control, Lipofectamine® 2000 was prepared following the 
manufacturer's transfection protocol. 
 
Fig. 3. (A) hBMP7 secretion (ng⁄ml) at 24 h (bars). Values represent mean ± SD (n = 3). P < 0.05 
versus L2K. (B) Phase contrast micrographs of NT2 cells 24 h post-transfection (B1) control, (B2) 
hBMP7-DPP80-transfected, (B3) hBMP7-L2K-transfected cells. (Scale bars = 50 μm). 
 
 
5.2.6. In vitro culture and proliferation assay of C6 glioma cells 
The rat glioma cell line (C6, CCL-107) was grown in the ATCC-formulated F-12K Medium 
(Catalog No. 30-2004). To make the growth medium (GM), fetal bovine serum was added to a 
final concentration of 2.5%, horse serum to a final concentration of 15%, 100 U/ml of penicillin, 
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and 100 μg/ml of streptomycin. Cells were maintained at a humidified atmosphere at 37 °C with 
5% CO2 and were used at the third passage. 
In 24 multiple-well culture plates, C6 cells were seeded (100.000 cells/well) overnight. The next 
day, GM was replaced with NT2-CM, both untransfected (+NT2) and transfected (+NT2-hBMP7). 
The C6-CM was prepared as mentioned in section 5.2.4. After 24 h, cell proliferation was 
determined using CCK8 assay according to the manufacturer's instructions. The wells where NT2-
CM was added were compared to “control” C6 glioma cells wells grown on C6-CM. 
5.2.7. Co-culture and Transwell migration assays 
The glioma cell migration assay was carried out using uncoated Transwell® 24 well microplates 
with 8.0 μm pore size. About 80.000 NT2 cells (of untransfected/transfected cultures (24 h post-
transfection) were seeded in the lower chambers and incubated at 37 °C for 4 h to ensure cell 
attachment. Then, C6 glioma cells (in 200 μl serum free media) were seeded in the upper Transwell 
insert (100.000 cells/insert). 16 h later, the medium was aspirated, and non-migratory cells were 
removed by swabbing the interior of the insert wells using cotton-tipped swabs. The migrating C6 
cells on the lower surface of the Transwell® membranes were fixed in methanol, stained with 
crystal violet (0.09% crystal violet) and counted under an inverted optical microscope (Nikon 
TSM). Five random fields were counted for each membrane, and the mean values from three 
independent experiments, performed in triplicate, were used. 
5.2.8. Statistical analysis 
Statistical differences between groups (significance levels of ˃95%) were calculated using 
ANOVA and Student's t-test. The values of p< 0.05 were regarded to be significant. Samples' 
normal distribution and homogeneity of the variance were evaluated with the Kolmogorov-
Smirnov and the Levene tests, respectively. All numerical data were presented as mean ± SD. 
5.3. Results 
5.3.1. Physicochemical features of niosomes/nioplexes 
Fig. 2-A depicts both size and ZP assessment of DPP80-hBMP7nioplexes at mass ratios 2/1 
through 14/1. The size of nioplexes (bars) gradually decreased from 190 nm to 90 nm at cationic 
lipid/DNA mass ratios of 2/1 and 14/1, respectively. With regard to surface charge, ZP readings 
gradually increased from −5.2 mV at 2/1 mass ratio to +35.5 mV at 10/1 mass ratio without any 
notable change thereafter. As illustrated in Fig. 2-B, the cryo-TEM-examined nioplexes (6/1 mass 
ratio) depicted imperfect spherical particles. Fig. 2-C represents gel retardation assay of nioplexes 
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prepared at different cationic lipid/DNA ratios (4/1, 6/1, 8/1 and 10/1). Such nioplexes 
demonstrated satisfactory ability to hold DNA, since most of the DNA signal was observed in the 
corresponding wells (4, 7, 10 and 13 lanes), and only faint SC bands were observed. Interestingly 
enough, the restrained DNA was liberated upon adding SDS, since no clear bands were observed 
in wells 5, 8, 11 and 14. Moreover, the DNA was protected from the DNase I enzyme, since clear 
OC (open circular) and SC (supercoiled) bands were detected in the 6th, 9th, 12th and 15th lanes, 
compared to the 3rd lane (free DNA). 
5.3.2. In vitro transfection of NT2 cells 
The secretion of hBMP7 by transfected/untransfected NT2 cells at 24 h post transfection is 
observed in Fig. 3-A (bars). Throughout the studied cationic lipid/DNA mass ratios, the ratios of 
6/1 and 8/1 depicted significant secretion of hBMP7 in comparison to the un-transfected “ctrl” 
cells (p < 0.05). The ratio of 6/1 was the highest transfection results (5.7 ng/ml), although it was 
still inferior to the secretion obtained by L2K transfection (18 ng/ml, p < 0.05). On the other hand, 
CCK8 assay demonstrated that cell viability was almost inversely related to the mass ratio of 
cationic lipid/DNA (Fig. 3, line graph). At the mass ratio of 6/1, peak of hBMP7 secretion, cell 
viability was still higher than that of L2K (63.6% and 59.5%, respectively, p < 0.05). Control NT2 
cells were epithelial-like adherent cells (Fig. 3-B1). One-day post-transfection, cells treated with 
DPP80 or L2K formulations, appeared more polyhedral with elongated processes (Fig. 3-B2 and 
3-B3, respectively). 
5.3.3. In vitro proliferation assay of C6 glioma cells 
In order to measure the functionality of secreted hBMP7 on glioma cells, rat C6 glioma cells were 
treated with the conditioned media of untransfected (NT2-CM) and transfected (NT2-hBMP7-
CM) cells. The NT2-CM significantly inhibited the cell growth of C6 cells, whether transfected 
(+NT2-hBMP7-CM) or untransfected (+NT2-CM) when compared to the C6-CM (*P < 0.05) (Fig. 
4). However, the anti-proliferative effect of the CM retrieved from transfected and untransfected 
NT2 cells was almost the same (P > 0.05). 
5.3.4. Transwell migration assay of C6 glioma cells 
Subsequently, the effect of hBMP7 secretion on C6 glioma cell migration was evaluated. As seen 
in Fig. 5, the migration of C6 cells was notably less (*P < 0.05) when co-cultured with transfected 





The high mortality rate and aggressiveness in GBM patients has necessitated the search for novel, 
safe, and effective therapeutic approaches. Over the past few years, both cell and gene therapies 
have offered great promise in this realm. 
In this study, we aimed to investigate the effectiveness of the newly synthesized cationic niosomes 
(DPP80) for transfecting NT2 cells, thus obtaining hBMP7-overexpressing NT2 cells. Such 
cationic niosomes were electrostatically complexed with the negatively charged pUNO1-hBMP7 
plasmid rendering nioplexes at different cationic lipid/DNA mass ratios. Despite the lack of 
consensus over the optimal size of non-viral gene carriers, it is widely accepted that the particle 
size clearly affects their performance. In the current work, the size of nioplexes was clearly affected 
by the cationic lipid/DNA mass ratio (Fig. 2-A). At the mass ratio of 2/1, the size was almost 190 
nm. Alongside higher mass ratios, the size gradually decreased, and this was most likely due to 
the electrostatic interactions that condense DNA plasmids more tightly. Not only their size, but the 
shape of non-viral complexes can also affect their final performance in gene delivery [3]. Our 
complexes were not perfectly regular in shape (Fig. 2-B) which could be due to the in-corporation 
of non-ionic surfactants on the surface of niosomes. As well, the discrete morphology of nioplexes 
at 6/1 mass ratio (Fig. 2-B) may be attributed to the high positive surface charge (˃ 29 mV), which 
in turn evades the particles’ aggregation through electrostatic repulsion [17]. The electrostatic 
interactions between the DNA (negatively charged phosphate groups) and the cationic niosomes 
(positively charged amine groups) play a crucial role during the transfection process as a precise 
balance between DNA capture and release needs to be achieved [18]. To investigate that parameter, 
gel retardation assay was carried out (Fig. 2-C). We selected nioplexes at cationic lipid/DNA mass 
ratios higher than 2/1 since the values of ZP were within the positive range (Fig. 2-A, lines). 
Interestingly, at all studied cationic lipid/DNA ratios, the niosomes were not only able to partially 
condense and totally release DNA upon adding SDS in all the cationic lipid/DNA mass ratios 
tested, but also to protect DNA against the enzymatic digestion, which is of significance in relevant 
in vivo applications. 
Thanks to the previously mentioned desirable characteristics of DPP80-hBMP7 nioplexes, we 
went on to carry out an in vitro transfection study in order to evaluate the capacity of nioplexes to 
deliver pUNO1-hBMP7 plasmid into NT2 cells. Besides being regarded as a stable cell line 
suitable for transfection studies, NT2 cells have been reported to be a promising source of human 
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 cells in CNS-targeted cell therapy applications [19]. 
 
Interestingly, NT2 cells have successfully induced recovery in pre-clinical stroke models. 
Therefore, they have been endorsed in several clinical trials [20]. In particular, their intrinsic 
glioma-tropism has opened up new avenues for brain malignancy therapeutics. NT2 cells are 
advantageously amenable to scale-up cell production, thus might represent a delivery vehicle for 
cancer therapy [21]. The transfection data (Fig. 3) revealed the release of significant amount of 
hBMP7 (5.7 ng/ml) at the mass ratio of 6/1 (cationic lipid/ DNA) where the cytotoxicity on NT2 
cells was less compared to positive control L2K (p < 0.05). 
These results suggest that the BMP7-secreting NT2 cells could be used as an interesting platform 
for further in vivo studies on the nervous tissue as well as other tissues where the production of 
BMP7 is desired. Despite the comparatively low level of hBMP7 secretion (5.7 ng/ml) by 
transfected NT2 cells, a markedly low dose of hBMP7 (1 ng/ml) could increase SMAD 
phosphorylation 5–6 fold, thus having a significant therapeutic effect [5]. A low, yet continuous 
dose of hBMP7 expression could be both neuroprotective and differentiation-inductive [22]. 
Similarly, our research team has recently reported a marked impact of hBMP7 production, even at 
much lower expression values, to induce spontaneous osteogenic differentiation of mesenchymal 
stem cells [3]. 
Fig. 4. In 
vitro 
viability 















Interestingly, a dose of 1.3 ng/ml of hBMP7 was enough to enhance the alkaline phosphatase 
activity and osteogenic matrix deposition, suggesting the effectiveness of such low concentrations 
of hBMP7 to achieve appropriate biological activities [5]. We then proceeded to evaluate the 
outcome of NT2-expressed hBMP7 on glioma cells. C6 glioma cells are stable, in vitro and in 
vivo, and express glioma-specific markers [23]. Thereafter, they are widely used in experimental 
studies for the treatment of gliomas [24]. An in-direct co-culture system by culturing tumor C6 
cells in the CM of NT2 cells was adopted to avoid the drawbacks of the direct co-culture system. 
In particular, the difficulty to evaluate the effect of one type of cells on another type. 
The overexpression of hBMP7 can alter the NT2 gene expression and suppress their own 
tumorigenesis, making them a safe candidate for in vivo studies [25]. Moreover, activation of 
BMP7 signaling in glioma cells could render them more vulnerable, and thereby more sensitive to 
low doses of chemotherapeutic drugs [26]. 
In accordance with Li and colleagues [27], the anti-glioma effect of NT2-CM could be mediated 
by the inactivation of mitogen activated protein kinase (MAPK) pathway. On the other hand, we 
observed (Fig. 4) that the overexpression of hBMP7 “per se” did not add any inhibitory effect on 
the viability of C6 cells. This effect could most probably be attributed to the presence of anti-BMP 
signals in the remaining serum content of NT2-CM, such as cytokines, noggin or chordin. The 
main goal of most antitumor drugs is to reduce cancer cell viability. However, because of the 
hyper-mutability of GBM cells, adjuvant anti-migration strategies are also desirable. 
Among others, Chirasani and co-workers [28] have reported, in agreement with our findings, the 
ability of BMP7-expressing neural precursor cells to attenuate the tumorigenicity of glioblastoma 
cells as well as to induce glioma stem cell differentiation [29]. Regarding the observed suppression 
of migration effect, it should be noted that BMP7 may have contradictory effects depending on the 
cell line being investigated [30]. The discerned anti-migratory effects of hBMP7-transfected NT2 
cells (Fig. 5) could be attributed to the negative effect of hBMP7 on cell motility (across uncoated 
Transwell filters) [31] or to the induction of tumor stem cell differentiation/senescence [26]. Thus, 
further studies on the exact mechanism are still required. This study represents a proof of concept 
that NT2 cells could be transfected with hBMP7 expression plasmids using the DPP80 cationic 
niosome gene carrier. Subsequently, the tumor-suppressive effect of hBMP7-expressing NT2 cells 
were investigated on the glioma cell line C6. The current preliminary data suggest that the NT2 
cell-based gene delivery of hBMP7 could be further explored in animal models as a novel 
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therapeutic approach to inhibit the proliferation and migration of gliomas. Adequate understanding 
of the underlying mechanisms is necessary for the development of effective cellular delivery 
vehicles for glioma therapy. 
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The use of stem cells as a biological therapeutic tool, including being a vehicle for gene delivery, 
has created a wide range of possible clinical applications. Various types of stem cells would 
typically express therapeutic genes to be delivered at targeted sites. With this in mind, 
mesenchymal stem cells (MSCs) and human neuronal precursor NT2 cells exhibit ideal features 
for vast gene therapeutic applications. To mention a few, both cell types depict marvelous selective 
migratory capacity, poor tumorigenicity, and a differentiation potential. Moreover, can be 
genetically manipulated to express selected therapeutic genes implicated in regenerative and 
cancer mechanisms. Non-viral carrier-based gene therapy is receiving the most attention recently, 
as relatively safe vehicles for gene transfer. One of the most promising non-viral gene carriers are 
the niosomes. Nevertheless, their use is hampered by their limited efficacy to deliver genes to the 
target cells. The main objective of this thesis is the use of novel cationic niosome vehicles to 
transfect stem cells (MSCs and NT2 cells) to induce hBMP7 overexpression. Therefore, in the 
present study, we have prepared and characterized cationic niosomes, based on the cationic lipid 
2,3-ditetradecyloxypropan-1 amine (DTPA), to be further used to transfect MSCs and NT2 cells 
for various applications. 
6.1. Stem cell-based gene delivery mediated by cationic niosomes for bone regeneration 
Our novel DP80 niosomes were formulated of the cationic lipid salt (DTPA-HCl) and the non-
ionic surfactant polysorbate 80 (Fig 1). Although the DTPA cationic lipid has been used for gene 
delivery applications,[1] this study was the first time to use it in a niosome formulation.  
 
 
Structurally, DTPA-HCl is composed of the four crucial elements that govern gene transfection, 
namely, the polar head, backbone, linker and two non-polar tails.[2] During the elaboration of 
Figure 1: Chemical structure of the 
components of DP80 niosomes (A. 
Cationic lipid DTPA-Cl, B. Polysorbate 
80) 
 
  Chapter 6 
102  
niosomes, we endeavored to circumvent the potential cytotoxicity of the ether linker of DTPA-
HCl by decreasing its molar ratio in proportion to P80 (DTPA-Cl to P80 as 1:2, respectively). 
Once synthesized, DP80 niosomes depicted appropriate nano-scaled size for gene delivery 
purposes (54.0±0.9 nm). The high positive zeta values (41.9±7.1 mV) is believed sufficient to 
ensure long-term stability[3] and spontaneous electrostatic interaction with plasmid DNA. 
Additionally, it could enhance proper binding of the resulting nioplexes to the negatively charged 
cell coat prior to nioplexes internalization.[2] Yet, the previously mentioned parameters “per se” 
could not ensure optimal behavior of the DP80 niosomes. 
To probe the actual behavior of our niosomes, as a proof of concept, DP80-EGFP-nioplexes were 
obtained by adding pCMS-EGFP reporter plasmid to DP80 niosomes at different cationic 
lipid/DNA mass ratios. A gradual decrease in the size of nioplexes was observed (168 - 84 nm, 
Fig.2-A, bars), at mass ratios increased up to 16/1. Such decline in size is governed by balanced 
events in a delicate multistep self-assembly process of complex formation, such as: electrostatic 
interaction, further membrane merging, lipid mixing and aggregate growth.[4] 
 
The size of nioplexes is important for proper interactions with cell components (organelle 
membranes and cytoskeletal filaments). The small size of nioplexes might be advantageous to 
improve the rate of cellular uptake.[5] In addition, nioplexes would be able to navigate the 
mammalian cytoskeleton with mesh size about 200 nm.[6] Regarding the ZP values (Fig.2-A, line), 
the gradual initial increase of superficial charge along with cationic lipid/DNA ratios (w/w), 
followed by a plateau phase, demonstrated the ability of cationic niosomes to bind to and neutralize 
Figure 2: (A) Effect of cationic 
lipid/DNA ratio (w/w) on both 
particle size (bars) and ZP (line), n = 
3. (B) Cryo-TEM micrographs of 
nioplexes at 16/1 cationic lipid/DNA 
ratio (w/w). Arrows indicate lamellar 
pattern. Scale bar =200 nm (inset 
scale bar =50 nm). (C) Binding, SDS-
induced release and protection of 
DNA at different cationic lipid/DNA 
ratios (w/w) of DP80-EGFP- 
nioplexes visualized by agarose 
electrophoresis. Nioplexes were 
treated with SDS (lanes 2, 5, 8, 11 and 
14) and DNase I + SDS (lanes 3, 6, 9, 
12 and 15). OC: open circular form, 
SC: supercoiled form. 
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the negatively charged phosphate groups in plasmid DNA.[7] At small cationic lipid/DNA mass 
ratios (2/1 and 4/1), the ZP readings were negative and shifted to the positive territory (around +20 
mV) at 8/1, 12/1, 16/1, and 20/1 mass ratios. At higher ratios, nioplexes were figured to function 
as gene delivery carriers taking advantage of their positive surface charge that facilitates proper 
electrostatic interaction with the anionic glycocalyx during the early steps of the endocytosis.[8] 
Nevertheless, other studies have reported a similar uptake of negatively and positively charged 
complexes. Therefore, the limiting step in transfection efficiency lies not in the process of 
internalization, but in the intracellular trafficking later on.[9] 
The shape of complexes has a marked effect on their performance as a gene delivery candidate,[10] 
Yet, the effect of particle shape on biological interactions is not fully understood. As reviewed by 
Champion et al,[10] vast studies proved the complexity of cell interactions with particles and 
revealed the ability of cells to respond differently to different particle shapes.  
Figure 3: D1-MSCs 
culture (A1), osteogenic 
(A2) and adipogenic 
differentiation (A3). (B) 
Cell transfection 
efficiency and viability at 
different cationic 
lipid/DNA ratios (w/w). 
Percentage of EGFP-
positive cells (bars), 
percentage of viable cells 
(line) and MFI (dashed 
line), (n = 3). Similar 
symbol (§) indicate 
insignificant differences 
among three bars 
(P˃0.05). *P < 0.05 vs. 
TransIT® 2020 and 
L2000 viability. #P < 
0.05 vs. TransIT® 2020 
and L200 MFI. (C) 
Representative overlay micrographs of D1-MSCs 48 h post-transfection via (C1) DP80-EGFP nioplexes 
(16/1 cationic lipid/DNA mass ratio) and (C2) TransIT® 2020. Scale bars: A1, A2, B1 and B2 = 50 μm and 
A3= 25 μm. 
For instance, non-spherical particles were reported to be internalized faster than the perfectly 
spherical ones.[5, 11] In our study, the cryo-TEM micrographs (Fig 2-B) illustrated that most of 
the DP80-EGFP complexes were not perfectly spherical. Additionally, the discrete morphology of 
nioplexes with no aggregates could be attributed to the moderately positive surface charge of 
nioplexes. Interestingly, the lamellar pattern observed in several nioplexes is believed to take place 
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during the process of complex formation due to the topological transformation of both DNA and 
lipid into compact quasi-spherical complex particles, with diameter of ~ 200 nm, depicting an 
ordered multi-lamellar planar structure (Fig 2-B, arrows).[12] The regular lamellar spacing of 
almost 5.5-6 nm (Fig 2-B inset) was similar to that reported by Le Bihan and colleagues, denoting 
the repetitive motif that corresponded to DNA strands being complexed with the lipid bilayers.[13] 
Figure 4: Uptake study of D1-MSCs 4 h post-incubation with FITC-labeled nioplexes. (A) Representative 
dot plots for cellular uptake, (A1) naked DNA (no carrier), (A2) DP80 nioplexes. (B) Uptake % (FITC-
positive cells) in the presence/absence of endocytosis inhibitors. (Ctrl) represents the uptake with no 
inhibitors. Mean ± SD; n = 3. (*p<0.05, *** p< 0.0001) 
Among the factors that can influence the transfection process is the electrostatic interaction 
between the phosphate groups of DNA (negatively charged) with the amine groups of cationic 
lipid (positively charged).[7, 14-16] With the help of gel retardation assay, we observed that at all 
cationic lipid/DNA ratios evaluated, niosomes were able to capture, release and shield DNA from 
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enzymatic degradation (Fig 2-C). Once we evaluated that DP80-EGFP nioplexes might be a 
suitable gene delivery vehicle, we proceeded to evaluate their biological performance in vitro. BM-
MSCs are of utmost importance in bone repair as they home to the fracture site, proliferate, and 
differentiate into bone-forming cells. Therefore, BM-derived D1-MSCs were selected for the 
current study. They were known to represent a multipotent platform holding potential for 
osteogenic fate determination in vitro.[17, 18] Moreover, their phenotypic characteristics and 
osteogenic differentiation potential (Fig 2-A) were reported to be consistent with human primary 
MSCs.[17, 19] Nevertheless, primary MSCs should be further studied to ensure the ability of our 
gene carriers to transfect them.  
 
Figure 5: Physicochemical characterization of DP80-hBMP7 nioplexes. (A) Effect of cationic lipid/DNA 
ratio (w/w) on particle size (bars) and zeta potential (line), n = 3. (B) Cryo-TEM micrographs of nioplexes 
at ratio of 8/1 cationic lipid/DNA ratio (w/w). Arrows indicate lamellar pattern. Scale bar = 500 nm (inset 
scale bar =100 nm). (C) Binding, SDS-induced release and protection of DNA at different cationic 
lipid/DNA ratios (w/w) of DP80-hBMP7 nioplexes visualized by agarose electrophoresis. Nioplexes were 
treated with SDS (lanes 2, 5, 8, 11 and 14) and DNase I + SDS (lanes 3, 6, 9, 12 and 15). OC: open circular 
form, SC: supercoiled form.  
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There is a general belief that niosomes are well tolerated both in vitro and in vivo conditions.[9] 
Our results (Fig 3-B) illustrated that DP80 (16/1) induced transfection efficiency similar to that 
obtained by TransIT® 2020 and L2000 commercial reagents (35.8 %, 40.6% and 35.1%, 
respectively).  However, the MFI of the transfected cells (Figs 3-B and 3-C) were significantly 
higher with DP80 (1791 a.u.) compared to TransIT® 2020 (1006 a.u). However, cell viability 
reported with DP80-EGFP nioplexes was significantly higher than that with L2000, while inferior 
to that reported by TransIT® 2020 commercial reagents. Such cytotoxicity might be induced, even 
in part, by GFP-induced apoptosis that might result from GFP aggregations or free radicals.[20] 
In general, the main aim of gene delivery is to attain overexpression of the transfected gene to 
express the protein in super physiological doses. Thereafter, transfection efficiency is not only a 
matter of how many cells were transfected, but also the amount of gene expression by the 
transfected cells. 
 
Figure 6: hBMP7 secretion (pg⁄mL) compared to untransfected cells (Ctrl) and TransIT® 2020-transfected 
cells (Bars). CCK-8 viability assay (line). Values represent mean ± SD (n = 3). Different symbols above 
bars indicate statistically significant differences. *P < 0.05 compared to all data points of line graph.  
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The high transfection efficiency values observed were preceded by a great percentage of nioplexes 
uptake as shown for best transfection efficiency (16/1) (Fig 4-A). However, despite the reported 
high uptake percentage (~ 83%), the performance of non-viral vectors is known to be clearly 
affected by their distinct cellular internalization pathway, taking into account the variable 
effectiveness of every pathway in the release of DNA into the cytoplasm, which is one of the 
critical steps in the eventual transgene expression.[9]Therefore, we further analyzed intracellular 
trafficking of our nioplexes by blocking the caveolae-mediated endocytosis (CvME), clathrin-
mediated endocytosis (CME) and macropinocytosis (MPC). The selected endocytosis mechanisms 
are reported as the most important endocytosis pathways in mammalian cells.[5, 21] Nonetheless, 
more pathways (as caveolae/clathrin independent and lipid raft-mediated endocytosis) should be 
investigated before a sound inference is made. The results observed in figure 4-B suggested that 
the main internalization of DP80-EGFP was through CvME and CME with no significant 
difference in between. Although a robust consensus does not exist, it is widely accepted that the 
endolysosomal fate is the hallmark feature of CME.[22, 23] Oppositely, CvME and/or MPC routes 
could be advantageous to avoid lysosomal degradation, which could ensure a better plasmid 
delivery and integrity.[21, 24] 
Consequently, the relevant contribution of the CME pathway, that routes nioplexes to lysosomes, 
could explain the relatively low transfection efficiency values observed (~36%, Fig 3-B), despite 
the fact that high number of cells (83%, Fig 4-A) captured the complexes. 
The promising results obtained with the reporter EGFP plasmid encouraged us to explore hBMP7 
gene transfection. As done before with DP80-EGFP nioplexes, we characterized DP80-hBMP7 
nioplexes regarding their physicochemical features. A gradual decline in size paralleled the 
increased cationic lipid/DNA mass ratio (Fig 5-A, bars). Starting from mass ratio of 4/1, ZP values 
were found in the positive range fluctuating between 18.3 and 26.2 mV. Particles were of no 
perfect shape and mostly acquired the planar lamellar pattern (Fig 5-B). Similar to what has been 
reported in figure 2-C, DP80-hBMP7 nioplexes were able to bind, release and protect plasmid 
DNA against DNase I enzymatic digestion (Fig 5-C). These findings suggested that DP80-hBMP7 
nioplexes could probably transfect D1-MSCs. The hBMP7 secreted after 48 h of transfection (Fig 
6) reached its highest value at the ratios of 4-12/1 (up to 1460 pg/ml). These results showed that 
the mass ratios of best transfection efficiency changed with different plasmids used (EGFP at 
16/1). 
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Figure 7: Osteogenic differentiation in vitro (A) Validation of ALP activity of the conditioned media of 
D1-MSCs, n=5. * indicated statistically significant differences (P < 0.05). ns indicated no statistically 
significant differences (P ≥ 0.05). (B) Representative light micrographs of D1-MSCs culture after Von 
Kossa staining for calcium deposition. Scale bars = 40µm. GM= Growth Medium, OM = Osteogenic 
Medium. (C) TEM micrographs for cell ultrastructure in both untransfected (C1) and transfected (C2) 
cultures. Arrowhead points at Golgi complex, arrows point at extracellular matrix deposits. N = nucleus, n= 
nucleolus. Scale bars = 2 μm.  
 
The cytotoxicity (CCK-8) assay revealed that transfected cells seemed to proliferate more at 
transfection mass ratios of 8/1 and 12/1. We believed that this observation might be due to two 
main factors; first, the negligible cytotoxicity effect of our nioplexes on D1-MSCs at such ratios 
compared to the higher ratios (16/1 and 20/1); second, the mitotic activity of such cells could be 
enhanced by the over expressed hBMP7.[25] 
Although TransIT® 2020 has significantly induced efficient transfection (with hBMP7 expression 
of 2111.5 pg/ml, Fig. 6), it has extremely decreased cell viability to ~23%. This might be referred 
to the cytotoxic impact of the hBMP7-TransIT® 2020 lipopolyplexes that seemed to attenuate the 
initial population of hBMP7-expressing cells.[26] Since ELISA assay was performed as early as 
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48 h post-transfection, the number of TransIT® 2020-transfected cells was not obviously enhanced 
by the putative mitogenic effect of hBMP7 protein. 
Noteworthy, the results shown in figures 3-B and 6 elucidated that different plasmids could behave 
differently in regard to their transfection efficiency and cytotoxicity. In the current study, each of 
the plasmids EGFP and hBMP7 had a different length (5541bp and 4497bp, respectively) and 
different promotors. Therefore, the obtained nioplexes rendered different physicochemical 
characteristics, thus demonstrated discrepant behavior regarding transfection efficiency or cell 
viability.[27, 28]. 
We further assessed the effectiveness of hBMP7 overexpression to induce osteogenesis in vitro 
using the alkaline phosphatase activity ALP (Fig 7-A).The ALP, an important parameter of the 
osteoblastic phenotype, is required for mineralization, thus expressed early during osteoblast 
differentiation.[29] Both ALP assay and Von Kossa staining (Fig 7-B) of the mineralized bone 
nodules denoted that hBMP7 expression induced spontaneous osteoblastic differentiation and 
calcified matrix deposition under standard culture (with GM). The deposition of amorphous 
extracellular matrix was further shown at the ultrastructural level in figure 7-C2. During this 
process, the secreted hBMP7 was anticipated to interact with cell membrane receptors, which 
could induce a signaling cascade that lead to osteoblastic differentiation in autocrine and/or 
paracrine mode.[30] Nevertheless, BMP7 transfection did not manifest significant difference when 
cells were cultured in OM for two weeks (Fig 7-B3 vs. 7-B4). Therefore, further investigation is 
still needed to explain why the hBMP7 expression did not boost the osteogenic differentiation of 
cells when cultured in osteogenic media. Furthermore, in vivo/ex vivo experiments are highly 
encouraged to validate the efficient osteogenic potential of the transfected cells.  
6.2. DPP80 cationic niosome-based EGFP gene transfection of neuronal precursor NT2 cells 
and rat cortical cells 
Flattering properties of niosome-based stem cell transfection [31] and neurons in cerebral cortex 
and retina were recently reported. [32, 33] As well, reports on literature highlighted the benefits of 
combining two surfactants within the same formulation. [34, 35] Therefore, we decided to explore 
the impact of combining the non-ionic surfactants poloxamer 188 (P) to polysorbate 80 (P80) 
(shown in figure 8) in the same niosome gene delivery system based on the cationic lipid DTPA-
HCl. We aimed to compare DP80 to DPP80 as gene delivery carriers. 
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Our data illustrated that particle features were affected according to the type of surfactant 
implemented (Table 1). The difference in size was assumed due to the different hydrophilic-
lipophilic balance value (HLB) of the incorporated surfactant. For example, incorporating P80 
(with lower HLB value) resulted in nanovesicles with smaller size.[36] Nevertheless, the 
interaction between surfactant(s) and cationic lipid in niosomes, on the molecular level,  should 
not be excluded as an additional factor that could influence the size of nanovesicles.[37] 
  
Table 1 Components (in mg) and physical characterization of niosome formulations regarding 
particle size (nm), PDI, and zeta potential (mV). Note: Data represent mean±SD (n=3). 
Abbreviations: DTPA, 2,3-di(tetradecyloxy)propan-1-amine; PDI, polydispersity index. 
 
Niosomes Components (mg)  Characterization  
 DTPA Poloxamer 188 Polysorbate 80 Size PDI Zeta potential 
 (D) (P) (P80) (nm)  (mV) 
DP80 5 – 25 54.02±0.94 0.52±0.10 41.9±7.10 
DPP80 5 12.5 12.5 90.41±0.65 0.42±0.01 44.1±4.39 
 
Before the attempt to transfect cells, we opted to characterize the nioplexes at different cationic 
lipid /DNA ratios (Fig.9). Although there is no general consensus on the optimal particle size of 
formulations, it is now widely accepted that this parameter clearly influences their 
performance.[38] In addition, nioplexes’ size varies according to the cationic lipid/DNA mass 
ratio. Interestingly, when DNA was incorporated to obtain complexes at a mass ratio of 2/1, size 
Figure 8: Chemical structure of: (A) 
polysorbate 80, (B) poloxamer 188, and (C) 
cationic lipid DTPA. Abbreviation: DTPA, 
2,3-di(tetradecyloxy)propan-1-amine. 
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of DP80 and DPP80 exceeded 168 and 200 nm, respectively. However, at higher ratios, size 
decreased probably due to the electrostatic interactions that condense DNA plasmids more 
efficiently in multi-lamellar forms as discerned by cryo-TEM examination (Fig 9-B2 and 4, 
arrows). The morphology of complexes appears to affect their final performance as gene delivery 
carriers.[39] Interestingly, the discerned lamellar pattern of several nioplexes is believed to happen 
during the process of complex formation. The topological transformation of both DNA and lipids 
to form nioplexes would form string-like aggregates, depicting  multi lamellar configuration. [13]  
 
Figure 9: Characterization of DP80 and DPP80 complexes. Notes: (A) Particle size (nm) and ZP (mV). 
The data represent mean±SD (n=3). (B1–B4) Cryo-TEM pictures of nioplexes. arrows in B2 and B4 point 
to the multi-lamellar pattern. (C) agarose gel electrophoresis assay at different cationic lipid/DNA ratios of 
DP80 and DPP80 complexes (upper and lower panels, respectively), based on both formulations. lanes are 
shown as: 1–3, uncomplexed DNA; 4–6, mass ratio 2/1; 7–9, mass ratio 4/1; 10–12, mass ratio 6/1; and 
13–15, mass ratio 8/1. lanes 2, 5, 8, 11, and 14 depict niocomplexes treated with SDS, while lanes 3, 6, 9, 
12, and 15 were treated with DNase I+ SDS. OC and SC (open circular and supercoiled forms, respectively). 
Abbreviations: SDS, sodium dodecyl sulphate; ZP, zeta potential. 
 
The discrete arrangement of nioplexes at (cationic lipid/DNA) mass ratio of 6/1 (Fig 9-B) could 
be attributed to their moderate positive surface charge (˃ 20 mV).[7] DPP80 nioplexes depicted 
higher ZP values (˃ 30 mV), thus had less aggregates as they tend to repel each other.[39] Another 
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paramount factor that influences the transfection process is the Van der Waals interactions between 
the phosphate groups of DNA (negatively charged )and the amine groups of the cationic niosomes 
(positively charged).[40] To analyze such feature, we performed a gel retardation assay (Fig. 9-
C). For DPP80 niosomes, all cationic lipid/DNA ratios analyzed were able to release and protect 
plasmid DNA against the enzymatic digestion. Though, complexes based on DP80 niosomes (Fig. 
9-C) failed clearly to protect DNA. In spite of being able to condense and release DNA properly, 
the DNA protective capacity thanks to DP80 niosomes against enzymatic digestion is key for 
efficient gene delivery. We propose that electrostatic interactions between DNA and DP80 
niosomes at low N/P ratios (2/1 and 4/1) could strongly condense  DNA, albeit not sufficient to 
protect DNA. [15] That might be attributed to the net negative surface charge of the nioplexes at 
the aforementioned low N/P ratios. 
Figure 10: Transfection studies in NT2 culture cells. (A) Flow cytometry analysis of percentage of cells 
that express EGFP (bars) and percentage of live cells (lines) at different cationic lipid/DNA ratios (w/w). 
Values represent mean±SD (n=3). *P,0.05 compared with DP80 at 6/1 and L2K at 2/1. Overlay of 
fluorescence and DIC pictures of control cells (B1), DP80 at 6/1 (B2), DPP80 at 6/1 (B3), and L2K at 2/1 
mass ratios (B4). scale bars=100 µm. (C) Mean fluorescence intensity (a.u.). Abbreviations: a.u., arbitrary 
unit; ctrl, control; DIC, digital image correlation; L2K, Lipofectamine® 2000.  
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Afterwards, both types of nioplexes were analyzed to evaluate in vitro NT2 transfection efficiency 
and cell viability. NT2 cells have been utilized in vivo as a promising human cell source for 
therapeutic application in several neurological disorders.[41, 42] Their therapeutic potential lies, 
mainly, in their ability to terminally differentiate into stable post-mitotic neurons, upon retinoic 
acid treatment, even long time after transplantation in animals’ brain tissue.[43] In addition,, NT2-
mediated recovery of preclinical models of stroke has justified their application in clinical 
trials.[44] Thanks to their stability and easy culture, NT2 cells are amenable to scale-up for cell 
production and represent a CNS-like gene/drug delivery vehicle for treatment of glioblastoma.[44-
46] In the current study, NT2 cells represent an interesting model to study the efficiency of gene 
delivery carriers into CNS due to their differentiation potential to neuronal as well as glial cell 
types.[47]  
Figure 11: Trafficking 
studies in NT2 culture 
cells. (A) Flow 
cytometry 
measurement of the 
percentage of cells that 
captured plasmid 
labeled with FITC. 
error bars represent SD 
(n=3). *P,0.05 





plasmids, and DP80 and 
DPP80 niocomplexes 
(at 6/1 mass ratios), 
respectively (scale 
bar=25 µm). (C) 
confocal micrographs 
showing intracellular 
distribution of DPP80 complexes, where plasmid is labeled in green color, and AlexaFluor 546-Transferrin 
(C1), AlexaFluor 555-Cholera Toxin (C2), AlexaFluor 594-Dextran (C3), and LysoTracker red DND-99 
markers (C4), all in red. Nuclei of cells were stained with DAPI-fluoromount G (blue) (scale bar=25 µm). 
Abbreviations: CME, clathrin mediated endocytosis; CvME, caveolae mediated endocytosis; FITC, 
fluorescein isothiocyanate; M, Mander’s co-localization coefficient; MPC, macropinocytosis.   
 
The data of cell transfection (Fig. 10-A) revealed the impact of surfactant (s) composition of the 
formulation. When P80 was used (in DP80), the values of transfection started to increase at the 
mass ratio of 6/1. Nioplexes at lower ratios (2/1 and 4/1) had failed to protect DNA from DNase 
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digestion (Fig. 9-C) which could explain the low transfection efficiencies at those ratios. However, 
the incorporation of P in the DPP80 niosome formulation had markedly enhanced the transfection 
at the lower ratios (2/1 and 4/1), compared to that of DP80, and maintained sufficient transfection 
at the higher ratios. The complexes depicted a positive ZP at low mass ratios (Fig 9-A), compared 
to the negative charge of DP80, which would enhance cell uptake, thus transfection (Fig 10-A).[48] 
Yet, the actual mechanism is not fully understood. At the cationic lipid/DNA mass ratio of 
maximum transfection (6/1), DPP80 depicted an interestingly higher MFI compared to DP80. In 
practice, one of the serious concerns in gene therapy is to obtain sufficient protein expression to 
ensure physiological effects. Thus, the amount of protein expression by the transfected cells (as a 
translation of the transfected gene) needs to be considered in addition to the percentage of 
transfected cells when designing a new gene carrier.[31]  
In regard to cell viability, DPP80 niosomes had cytotoxic effect less than that of DP80 at tested 
mass ratios. NT2 cell viability at 6/1 mass ratio significantly exceeded that reported by liposome-
based transfection reagent (L2K). This represents an appealing feature for further in vivo 
applications where cytotoxicity is of utmost importance. The higher cationic lipid/ DNA mass 
ratios of DPP80 nioplexes depicted a marked cytotoxic effect which was even higher in case of 
their DP80 counterparts. Further studies are needed to fully explain the reported increase in 
cytotoxicity. 
The fact that the type and amount of surfactant would influence the biological function of 
niosomes,[49] might explain the modest transfection and viability results observed when only P 
(supplementary data, Fig.S1) or P80 (Fig 10-A) surfactants were used in niosome formulations 
(DP and DP80, respectively). In addition, when the liposomes were manufactured in the absence 
of surfactants (referred to as D, Fig.S1), both transfection efficiency and cell viability values were 
way less than their DPP80 counterparts. To understand the transfection process in NT2 cells 
mediated by DPP80 complexes, we evaluated the cellular uptake and the intracellular distribution 
of complexes, since those two factors could markedly affect the final performance of gene delivery 
carriers.[9] Cellular uptake values of DPP80 complexes were compared to that of DP80 and L2K. 
As observed in Fig.11-A, cell uptake for DPP80 nioplexes exceeded that of DP80. That could be 
due to their higher net positive ZP value (Fig 9-A), or specific interactions between nioplexes and 
the lipid components of cell membrane.[12] Moreover, variations in the length of carbon chains 
and/or the number of unsaturated bonds (inside the carbon chains) of surfactants can affect the 
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permeability of different membranes towards nioplexes.[37] Anyway, the percentage of 
transfected cells with DPP80 complexes (30%, Fig.10-A) were clearly lower than the percentage 
of positive cells for FITC-labeled DPP80 complexes (95%, Fig.11-A), which suggested the 
potential influence of other biological processes, such as the uptake mechanism or endosome 
scape, in the eventual expression of EGFP.[50] Those biological processes deserve subsequent 
experiments to elucidate their effect on gene expression. Despite the lack of consensus on the most 
efficient endocytosis pathway, we proceeded to analyze three of the most important cellular uptake 
pathways (CME, CvME and MPC) that are strongly believed to affect the fate of internalized 
complexes.[51]  
 
Figure 12: EGFP gene 
expression in primary 
neuronal cell cultures (A1 and 
A2). GFAP+ve neuroglia (red) 
and nuclei were stained in blue 
color with Hoechst 33342 
(scale bars=40 and 20 µm, 
respectively). (B) in vivo 
expression green protein 
(scale bar=40 µm). Note: 
nuclei are shown in blue color 







The observed results in fig.11-C suggested that DPP80 complexes were mainly internalized by 
CvME and MPC, while CME had much less participation in their cellular uptake. Both CvME and 
CME are generally believed to be the endocytosis routes that transfer genetic material to late 
endosomes/lysosomes, where the acidic environment degrades the DNA, hampering the 
transfection process.[50] Therefore, co-localization of the complexes with late 
endosome/lysosome (Fig. 11-C4) could explain the great gap between the 95% of NT2 that 
captured DPP80 complexes (Fig 11-A), and the ~30% that eventually expressed EGFP (Fig 
10).[52] 
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Subsequently, before proceeding to in vivo studies, we evaluated the transfection efficiency of 
DPP80 nioplexes in primary cortical cultures derived from rat embryos. Primary culture is 
composed of several  
Figure S1 (A) Transfection efficiency of D liposomes and DP niosomes in NT2 cells. Percentages of cells 
that express green protein (bars) and live cells (lines). Values represent mean±SD (n=3). (B1 and B2) 
Overlay of fluorescence and DIC pictures of NT2 cells with D liposomes (6/1) and DP niosomes (2/1), 
respectively (scale bar=100 µm). Abbreviations: DIC, digital image correlation; T, transfection; V, 
viability.  
 
types of neurons and glial cells mixed to form neuronal-glial network set up. Initial data suggested 
that some neurons expressed EGFP (Fig. 12-A1). This observation was further confirmed by the 
lack of GFAP+ve immunoreactivity in those EGFP-expressing cells (Fig. 12-A2). Such preferential 
transfection of neurons encouraged us to proceed to in vivo experiments where direct intracranial 
injection of DPP80 complexes was performed. Despite the lack of toxicity signs in the cortical 
tissue after injection (data not shown), intravascular injections in larger animal models should be 
investigated in future studies. Unlike the observations in primary culture, neuroglia (NeuN-ve) were 
the only transfected cells (Fig.12-B). In general, discrepancies between in vitro and in vivo assays 
are not uncommon, and most probably due to the major differences in biological context.[53] The 
reported favorable transfection of glial cells might be attributed to their higher mitotic and/or 
phagocytic activities.[54] In addition, the number of glial cells constitute over 70% of the total cell 
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population in the CNS. On the other side, the incapacity of complexes to transfect neurons in vivo 
is probably due to the less uptake and/or the unfavorable intracellular trafficking.[55] Therefore, 
DPP80 complexes could be of great interest to transfect glial cells in the CNS in glia-related 
neurological disorders. Glia also play a pivotal role in the normal development and function of 
nervous tissue.[56] Their perturbation is associated with several neurological disorders such as; 
stroke, epilepsy, multiple sclerosis, Alzheimer’s and Parkinson’s diseases.[56, 57]  
These novel biocompatible nioplexes were able to induce in vivo transfection into glial cells in rat 
brains after intracortical administration. Interestingly, DPP80 nioplexes do not only represent a 
promising tool for direct in vivo transfection, but also for cell-based gene delivery applications 
where the transfected NT2 cells or their derived neurons can be used as a cell-based gene delivery 
carrier to deliver therapeutic genes for CNS disorders including glioblastoma.[58, 59] 
 
6.3. DPP80 cationic niosome-based hBMP7 gene transfection of neuronal precursor NT2 
cells to reduce the migration of glioma cell line 
The high mortality rate in glioblastoma patients has necessitated the search for novel, safe, and 
effective therapeutic approaches. Over the past few years, both cell and gene therapies have offered 
great promise in this realm. In our previous work,[60] DPP80 cationic niosomes were able to 
transfect NT2 cells with EGFP reporter plasmid. Therefore, we were encouraged to investigate the 
effectiveness of these niosomes to deliver an expression plasmid (pUNO1-hBMP7) to NT2 cells, 
then determine their potential to combat glioma cell proliferation and/or migration in vitro. First, 
cationic niosomes were electrostatically complexed with the negatively charged pUNO1-hBMP7 
plasmids rendering nioplexes at different cationic lipid/DNA mass ratios. Although the optimal 
size of non-viral gene carriers is unknown as yet, it is widely accepted that the particle size clearly 
affects their performance. In the current work, the size of nioplexes was clearly affected by the 
cationic lipid/DNA mass ratio (Fig. 13-A). At the mass ratio of 2/1, the size was almost 190 nm. 
Alongside higher mass ratios, the size gradually decreased. Such decrease is most likely due to the 
electrostatic interactions that condense DNA plasmids more tightly. In addition to the size, the 
shape of non-viral complexes can also affect their final performance in gene delivery.[31] hBMP7-
DPP80 complexes were not perfectly regular in shape (Fig 13-B). As well, the discrete morphology 
of nioplexes at 6/1 mass ratio (Fig 13-B) may be attributed to the high positive surface charge (˃ 
29 mV) which, in turn, evades the particles’ aggregation via the electrostatic repulsion forces.[7] 
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The electrostatic interaction between DNA (negatively charged phosphate groups) and the cationic 
niosomes (positively charged amine groups) plays a crucial role during the transfection process, 
as a precise balance between the capture and release of DNA is necessary.[40] To investigate such 
parameter, gel retardation assay was carried out (Fig.13-C). We selected nioplexes at cationic 
lipid/DNA mass ratios higher than 2/1 since the values of ZP were within the positive range (Fig 
13-A, lines). Interestingly, at all studied cationic lipid/DNA ratios, the niosomes were not only 
able to partially condense and totally release DNA upon adding SDS, but also to protect DNA 
against the DNase enzymatic digestion, which is of significance for in vivo applications. 
Figure 13: (A) Particle size (nm) and Zeta potential (mV). Data represent mean ± SD (n = 3). (B) Cryo-
TEM micrographs of nioplexes at 6/1 cationic lipid/DNA mass ratio. Scale bar 500 nm (inset, 100 nm). (C) 
Gel retardation assay of nioplexes. Lanes 2, 5, 8, 11 and 14 depict nioplexes treated with SDS, while lanes 
3, 6, 9, 12 and 15 correspond to DNase I- and SDS-treated nioplexes. OC and SC: open circular and 
supercoiled forms, respectively. 
 
Thanks to the previously mentioned desirable features of DPP80-hBMP7 nioplexes, we proceeded 
to in vitro transfection in order to evaluate the capacity of nioplexes to deliver hBMP7 gene to 
NT2 cells. Besides being regarded as a stable cell line suitable for transfection studies, NT2 cells 
have been reported to be a promising source of human stem cells in CNS-targeted cell therapy 
applications.[42] Interestingly, NT2 cells have successfully induced recovery in pre-clinical stroke 
models. Therefore, they have been endorsed in clinical trials.[61] In particular, their intrinsic 
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glioma-tropism has opened new horizons to treat brain malignancies. NT2 cells are advantageously 
amenable to scale-up cell production, thus might represent a promising off-the-shelf gene delivery 
vehicle for cancer therapy.[62] The obtained transfection data (Fig. 14) revealed the release of 
significant amount of hBMP7 (5.7ng/ml) when the mass ratio of 6/1 (cationic lipid/DNA) was 
used for transfection. On the other side, Cytotoxicity on NT2 cells was less compared to the 
positive control, L2K (p < 0.05). These results suggest that the hBMP7-secreting NT2 cells might 
be used as an interesting platform for further studies on the nervous tissue, as well as other tissues 
where the production of BMP7 is desired. Despite the low level of hBMP7 secretion (5.7 ng/ml) 
by the transfected NT2 cells, a markedly low dose of hBMP7 (1 ng/ml) could increase SMAD 
phosphorylation 5–6 fold, thus having a significant therapeutic effect.[63] 
In their research work, Tsai et al. have reported that low, yet continuous secretion of hBMP7 was 
both neuroprotective and differentiation-inductive.[64] Similarly, our research team has recently 
reported a marked impact of hBMP7 production, even at much lower values, to induce spontaneous 
osteogenic differentiation of mesenchymal stem cells in vitro.[31] Interestingly, a dose of 1.3 
ng/ml of hBMP7 was enough to enhance the alkaline phosphatase activity and osteogenic matrix 
deposition, suggesting the effectiveness of such low concentrations of hBMP7 to achieve desired 
therapeutic activities.[63] We further proceeded to evaluate the impact of NT2-expressed hBMP7 
on glioma cells. Glioma C6 cells are known to express glioma-specific markers. In addition, they 
are stable both in vitro and in vivo.[65] Thereafter, they are widely used in experimental studies 
for the treatment of gliomas.[66] To avoid the drawbacks of the direct co-culture system, an 
indirect co-culture was adopted by culturing tumor C6 cells in the CM of NT2 cells. In particular, 
the difficulty to evaluate the effect of one type of cells on another type. The overexpression of 
hBMP7 can alter the NT2 gene expression and suppress their own tumorigenicity, making them a 
safe candidate for in vivo studies.[67] Moreover, activation of BMP7 signaling in glioma cells 
could render them more vulnerable, and thereby more sensitive to low doses of chemotherapeutic 
drugs.[68] 
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Figure 14: (A) hBMP7 secretion (ng⁄ml) at 24 h (bars). Values represent mean ± SD (n = 3). P < 
0.05 versus L2K. (B) Phase contrast micrographs of NT2 cells 24 h post-transfection (B1) control, 
(B2) hBMP7-DPP80-transfected, (B3) hBMP7-L2K-transfected cells. (Scale bars = 50 μm). 
 
In accordance with Li and colleagues,[69] the anti-glioma effect of NT2-CM could be mediated 
by the inactivation of mitogen-activated protein kinase (MAPK) pathway. On the other hand, we 
observed (Fig. 15) that the overexpression of hBMP7 “per se” did not add any inhibitory effect on 
the viability of C6 cells. This effect could most probably be attributed to the presence of anti-BMP 
signals in the remaining serum content of NT2-CM, such as cytokines, noggin or chordin. The 
main goal of most antitumor drugs is to reduce cancer cell viability. However, because of the 
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hyper-mutability of GBM cells, adjuvant anti-migration strategies are also desirable. Among 
others, Chirasani and co-workers [70] have reported, in agreement with our findings, the ability of 
BMP7-expressing neural precursor cells to attenuate the tumorigenicity of glioblastoma cells as 
well as to induce glioma stem cell differentiation.[71]  
 
Figure 15: In vitro viability assay of C6 glioma cells after incubation with; C6-CM, untransfected 
NT2 cells and transfected NT2 cells. (*P < 0.05).  
 
Regarding the observed suppression of migration effect, it should be noted that BMP7 may have 
contradictory effects depending on the cell line being investigated.[72] The discerned anti-
migratory effects of hBMP7-transfected NT2 cells (Fig. 16) could be attributed to the negative 
effect of hBMP7 on cell motility (across uncoated Transwell filters)  [73] or to the induction of 
tumor stem cell differentiation/senescence.[68] Thus, further studies on the exact mechanism are 
still required. Adequate understanding of the underlying mechanisms is necessary for the 
development of effective cellular delivery vehicles for glioma therapy. 




6.4. References  
1. Song, Y.K. and D. Liu, Free liposomes enhance the transfection activity of DNA/lipid complexes 
in vivo by intravenous administration. Biochim Biophys Acta, 1998. 1372(1): p. 141-50. 
2. Balazs, D.A. and W. Godbey, Liposomes for use in gene delivery. Journal of drug delivery, 2010. 
2011. 
3. Szunerits, S. and R. Boukherroub, Introduction to Plasmonics: Advances and Applications. 2015: 
CRC Press. 
4. Wasungu, L. and D. Hoekstra, Cationic lipids, lipoplexes and intracellular delivery of genes. J 
Control Release, 2006. 116(2): p. 255-64. 
5. Singh, J., et al., Evaluation of cellular uptake and intracellular trafficking as determining factors 
of gene expression for amino acid-substituted gemini surfactant-based DNA nanoparticles. Journal 
of nanobiotechnology, 2012. 10(1): p. 7. 
6. Majzoub, R.N., K.K. Ewert, and C.R. Safinya, Cationic liposome–nucleic acid nanoparticle 
assemblies with applications in gene delivery and gene silencing. Phil. Trans. R. Soc. A, 2016. 
374(2072): p. 20150129. 
7. Puras, G., et al., A novel cationic niosome formulation for gene delivery to the retina. J Control 
Release, 2014. 174: p. 27-36. 
8. Sakurai, F., et al., Effect of DNA/liposome mixing ratio on the physicochemical characteristics, 
cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and 
subsequent gene expression. J Control Release, 2000. 66(2-3): p. 255-69. 
Figure 16: Transwell 
migration assay of glioma C6 
cells co-cultured with 
transfected NT2 cells (+NT2-
hBMP7) compared to the 
untransfected cells (+NT2) (*P 
< 0.05). C6 glioma cells on the 
lower surface of Transwell 
inserts were stained with 
crystal violet (scale bar = 50 
μm). 
 
  Chapter 6 
123  
9. Mashal, M., et al., Retinal gene delivery enhancement by lycopene incorporation into cationic 
niosomes based on DOTMA and polysorbate 60. Journal of Controlled Release, 2017. 
10. Champion, J.A., Y.K. Katare, and S. Mitragotri, Particle shape: a new design parameter for micro-
and nanoscale drug delivery carriers. Journal of Controlled Release, 2007. 121(1): p. 3-9. 
11. Gratton, S.E., et al., The effect of particle design on cellular internalization pathways. Proceedings 
of the National Academy of Sciences, 2008. 105(33): p. 11613-11618. 
12. Ma, B., et al., Lipoplex morphologies and their influences on transfection efficiency in gene 
delivery. Journal of Controlled Release, 2007. 123(3): p. 184-194. 
13. Le Bihan, O., et al., Probing the in vitro mechanism of action of cationic lipid/DNA lipoplexes at a 
nanometric scale. Nucleic acids research, 2011. 39(4): p. 1595-1609. 
14. Ojeda, E., et al., The role of helper lipids in the intracellular disposition and transfection efficiency 
of niosome formulations for gene delivery to retinal pigment epithelial cells. International journal 
of pharmaceutics, 2016. 503(1): p. 115-126. 
15. Ojeda, E., et al., Niosomes based on synthetic cationic lipids for gene delivery: the influence of 
polar head-groups on the transfection efficiency in HEK-293, ARPE-19 and MSC-D1 cells. 
Organic & biomolecular chemistry, 2015. 13(4): p. 1068-1081. 
16. Puras, G., et al., Protamine/DNA/Niosome Ternary Nonviral Vectors for Gene Delivery to the 
Retina: The Role of Protamine. Mol Pharm, 2015. 12(10): p. 3658-71. 
17. Honda, Y., et al., Guiding the osteogenic fate of mouse and human mesenchymal stem cells through 
feedback system control. Scientific reports, 2013. 3: p. 3420. 
18. Hsiong, S.X., et al., Cyclic arginine-glycine-aspartate peptides enhance three-dimensional stem 
cell osteogenic differentiation. Tissue Engineering Part A, 2008. 15(2): p. 263-272. 
19. Garate, A., et al., Assessment of the behavior of mesenchymal stem cells immobilized in biomimetic 
alginate microcapsules. Molecular pharmaceutics, 2015. 12(11): p. 3953-3962. 
20. Jensen, E.C., Use of fluorescent probes: their effect on cell biology and limitations. The Anatomical 
Record, 2012. 295(12): p. 2031-2036. 
21. Xiang, S., et al., Uptake mechanisms of non-viral gene delivery. J Control Release, 2012. 158(3): 
p. 371-8. 
22. El-Sayed, A. and H. Harashima, Endocytosis of gene delivery vectors: from clathrin-dependent to 
lipid raft-mediated endocytosis. Molecular Therapy, 2013. 21(6): p. 1118-1130. 
23. Bareford, L.M. and P.W. Swaan, Endocytic mechanisms for targeted drug delivery. Adv Drug 
Deliv Rev, 2007. 59(8): p. 748-58. 
24. Kou, L., et al., The endocytosis and intracellular fate of nanomedicines: Implication for rational 
design. Asian Journal of Pharmaceutical Sciences, 2013. 8(1): p. 1-10. 
25. Xu, J., et al., BMP7 enhances the effect of BMSCs on extracellular matrix remodeling in a rabbit 
model of intervertebral disc degeneration. The FEBS journal, 2016. 283(9): p. 1689-1700. 
26. Bahrambeigi, V., et al., Non-viral gene transfer into murine adipose derived mesenchymal stem 
cells: A comparative study of different non-viral methods. Gene Therapy and Molecular Biology, 
2013. 15: p. 164-175. 
27. Hornstein, B.D., et al., Effects of Circular DNA Length on Transfection Efficiency by 
Electroporation into HeLa Cells. PloS one, 2016. 11(12): p. e0167537. 
28. Yin, W., P. Xiang, and Q. Li, Investigations of the effect of DNA size in transient transfection assay 
using dual luciferase system. Analytical biochemistry, 2005. 346(2): p. 289-294. 
29. Scarfì, S., Use of bone morphogenetic proteins in mesenchymal stem cell stimulation of cartilage 
and bone repair. World journal of stem cells, 2016. 8(1): p. 1. 
30. Dorman, L., M. Tucci, and H. Benghuzzi, In vitro effects of bmp-2, bmp-7, and bmp-13 on 
proliferation and differentation of mouse mesenchymal stem cells. Biomedical sciences 
instrumentation, 2011. 48: p. 81-87. 
31. Attia, N., et al., Stem cell-based gene delivery mediated by cationic niosomes for bone 
regeneration. Nanomedicine, 2018. 14(2): p. 521-531. 
  Chapter 6 
124  
32. Ojeda, E., et al., The influence of the polar head-group of synthetic cationic lipids on the 
transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials, 2016. 77: p. 
267-79. 
33. Ochoa, G.P., et al., A novel formulation based on 2,3-di(tetradecyloxy)propan-1-amine cationic 
lipid combined with polysorbate 80 for efficient gene delivery to the retina. Pharm Res, 2014. 31(7): 
p. 1665-75. 
34. Muzzalupo, R., et al., Niosomes containing hydroxyl additives as percutaneous penetration 
enhancers: effect on the transdermal delivery of sulfadiazine sodium salt. Colloids and Surfaces B: 
Biointerfaces, 2014. 123: p. 207-212. 
35. Wang, Y., et al., Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for 
intravenous delivery. Int J Nanomedicine, 2011. 6: p. 1497-507. 
36. Basha, M., et al., Design and optimization of surfactant-based nanovesicles for ocular delivery of 
Clotrimazole. Journal of liposome research, 2013. 23(3): p. 203-210. 
37. Bnyan, R., et al., Surfactant effects on lipid-based vesicles properties. Journal of pharmaceutical 
sciences, 2018. 107(5): p. 1237-1246. 
38. Pezzoli, D., et al., Size matters for in vitro gene delivery: investigating the relationships among 
complexation protocol, transfection medium, size and sedimentation. Scientific reports, 2017. 7: p. 
44134. 
39. Mady, M.M., et al., Biophysical studies on chitosan-coated liposomes. European Biophysics 
Journal, 2009. 38(8): p. 1127-1133. 
40. Eastman, S., et al., Biophysical characterization of cationic lipid: DNA complexes. Biochimica et 
Biophysica Acta (BBA)-Biomembranes, 1997. 1325(1): p. 41-62. 
41. Jain, K., Cell therapy for CNS trauma. Molecular biotechnology, 2009. 42(3): p. 367. 
42. Cacciotti, I., et al., Neuro-differentiated Ntera2 cancer stem cells encapsulated in alginate beads: 
First evidence of biological functionality. Materials Science and Engineering: C, 2017. 81: p. 32-
38. 
43. Hara, K., et al., Neural progenitor NT2N cell lines from teratocarcinoma for transplantation 
therapy in stroke. Progress in neurobiology, 2008. 85(3): p. 318-334. 
44. Hao, S. and B. Wang, Review on Intracerebral Haemorrhage: Multidisciplinary Approaches to the 
Injury Mechanism Analysis and Therapeutic Strategies. Current pharmaceutical design, 2017. 
23(15): p. 2159-2160. 
45. Frosina, G., Stem cell-mediated delivery of therapies in the treatment of glioma. Mini reviews in 
medicinal chemistry, 2011. 11(7): p. 591-598. 
46. Ahmed, A.U., N.G. Alexiades, and M.S. Lesniak, The use of neural stem cells in cancer gene 
therapy: predicting the path to the clinic. Current opinion in molecular therapeutics, 2010. 12(5): 
p. 546. 
47. Ferrari, A., et al., Immature human NT2 cells grafted into mouse brain differentiate into neuronal 
and glial cell types. FEBS letters, 2000. 486(2): p. 121-125. 
48. Midoux, P. and M. Monsigny, Efficient gene transfer by histidylated polylysine/pDNA complexes. 
Bioconjugate chemistry, 1999. 10(3): p. 406-411. 
49. Taymouri, S. and J. Varshosaz, Effect of different types of surfactants on the physical properties 
and stability of carvedilol nano-niosomes. Advanced biomedical research, 2016. 5. 
50. Goldshtein, M., et al., Mechanisms of cellular uptake and endosomal escape of calcium-siRNA 
nanocomplexes. International journal of pharmaceutics, 2016. 515(1-2): p. 46-56. 
51. Zhao, F., et al., Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. small, 
2011. 7(10): p. 1322-1337. 
52. Ruiz de Garibay, A.P., et al., Role of endocytic uptake in transfection efficiency of solid lipid 
nanoparticles‐based nonviral vectors. The journal of gene medicine, 2013. 15(11-12): p. 427-440. 
53. Puras, G., et al., Oligochitosan polyplexes as carriers for retinal gene delivery. European Journal 
of Pharmaceutical Sciences, 2013. 48(1-2): p. 323-331. 
  Chapter 6 
125  
54. Schafer, D.P. and B. Stevens, Phagocytic glial cells: sculpting synaptic circuits in the developing 
nervous system. Current opinion in neurobiology, 2013. 23(6): p. 1034-1040. 
55. Bergen, J.M., et al., Nonviral approaches for neuronal delivery of nucleic acids. Pharmaceutical 
research, 2008. 25(5): p. 983-998. 
56. Barres, B.A., The mystery and magic of glia: a perspective on their roles in health and disease. 
Neuron, 2008. 60(3): p. 430-440. 
57. Milligan, E.D. and L.R. Watkins, Pathological and protective roles of glia in chronic pain. Nature 
reviews neuroscience, 2009. 10(1): p. 23. 
58. Watson, D.J., et al., Genetically modified NT2N human neuronal cells mediate long-term gene 
expression as CNS grafts in vivo and improve functional cognitive outcome following experimental 
traumatic brain injury. Journal of Neuropathology & Experimental Neurology, 2003. 62(4): p. 368-
380. 
59. Longhi, L., et al., Ex vivo gene therapy using targeted engraftment of NGF-expressing human 
NT2N neurons attenuates cognitive deficits following traumatic brain injury in mice. Journal of 
neurotrauma, 2004. 21(12): p. 1723-1736. 
60. Attia, N., et al., Gene transfer to rat cerebral cortex mediated by polysorbate 80 and poloxamer 
188 nonionic surfactant vesicles. Drug design, development and therapy, 2018. 12: p. 3937. 
61. Manley, N.C., et al., Neural stem cells in stroke: Intracerebral approaches, in Cell therapy for 
brain injury. 2015, Springer. p. 91-109. 
62. Binello, E. and I.M. Germano, Stem cells as therapeutic vehicles for the treatment of high-grade 
gliomas. Neuro-oncology, 2011. 14(3): p. 256-265. 
63. Chitty, D.W., et al., Development of BMP7-producing human cells, using a third generation 
lentiviral gene delivery system. Journal of neuroscience methods, 2012. 205(1): p. 17-27. 
64. Tsai, M.J., et al., Dual effect of adenovirus‐mediated transfer of BMP7 in mixed neuron‐glial 
cultures: Neuroprotection and cellular differentiation. Journal of neuroscience research, 2007. 
85(13): p. 2950-2959. 
65. Benda, P., et al., Differentiated rat glial cell strain in tissue culture. Science, 1968. 161(3839): p. 
370-371. 
66. Guan, Y., et al., Effects of dexamethasone on C6 cell proliferation, migration and invasion through 
the upregulation of AQP1. Oncology letters, 2018. 15(5): p. 7595-7602. 
67. Caricasole, A., et al., Bone morphogenetic proteins (BMPs) induce epithelial differentiation of 
NT2D1 human embryonal carcinoma cells. International Journal of Developmental Biology, 2003. 
44(5): p. 443-450. 
68. Tso, J.L., et al., Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase 
expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Molecular cancer, 
2015. 14(1): p. 189. 
69. Li, Z., et al., Conditioned medium from neural stem cells inhibits glioma cell growth. Cellular and 
Molecular Biology, 2016. 62(12): p. 68-73. 
70. Chirasani, S.R., et al., Bone morphogenetic protein-7 release from endogenous neural precursor 
cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain, 2010. 133(7): p. 1961-
1972. 
71. Caja, L., C. Bellomo, and A. Moustakas, Transforming growth factor β and bone morphogenetic 
protein actions in brain tumors. FEBS letters, 2015. 589(14): p. 1588-1597. 
72. Lau, K.S.-K., The role of bone morphogenetic protein 2 in ovarian cancer migration. 2016, 
University of British Columbia. 
73. Savary, K., et al., Snail depletes the tumorigenic potential of glioblastoma. Oncogene, 2013. 
32(47): p. 5409. 
 
 


































  Chapter 7 
 
129  
According with the results obtained in this experimental work, the main conclusions include: 
 
1. DP80 nioplexes could transfect D1 MSCs with pCMS-EGFP and pUNO1-hBMP7 plasmids. 
Yet, optimization of the process of niosome formulation is required to enhance transfection 
efficiency and cell safety. 
2. The hBMP7-transfected D1-MSCs could be considered not only as an effective delivery tool 
of hBMP7, but also as a proliferating and bone-forming cells for bone regeneration purpose, 
which offers reasonable hope to use the approach of stem cell-based gene delivery by niosomes 
approach to target sites where bone regeneration is needed. 
3. To validate that hypothesis, additional in vivo experiments are still needed, since the consistent 
correlation of in vitro and in vivo experiments does always not exit. 
4. Our results showed that the DPP80 niosomes, elaborated with a mixture of both P and P80 
non-ionic surfactants, were efficiently able to transfect NT2 cells without compromising their 
viability after cellular uptake mainly mediated by CME and MPC. 
5. DPP80-EGFP complexes were able to preferentially transfect neurons in rat embryonic 
primary cortical cultures. 
6. The DPP80 gene carriers were able to induce direct in vivo transfection of glial cells in rat 
cerebral cortex after intracortical injection. 
7. Our results depicted the discrepancy between in vitro and in vivo transfection preference of the 
DPP80-EGFP complexes. In vitro, neurons were preferentially transfected. On the other side, 
glial cells were preferentially transfected in vivo. 
8. This study represents a proof of concept that NT2 cells could be transfected with hBMP7 
expression plasmids using the DPP80 cationic niosome gene carrier. 
9. The co-culture with either untransfected/transfected NT2 cells may reduce the viability of C6 
glioma cells. Nonetheless, the hBMP7-overexpressing NT2 cells hamper the migration of C6 
glioma cells. These results highlight the potential of NT2 cell-based delivery of hBMP7 for 
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